AAVBC

AMERICAN ACADEMY OF VALUE BASED CARE

COPD

Quick Reference Guide

2026

Table of Contents

CLINICAL SNAPSHOT

Definition: Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous lung condition characterized by chronic respiratory symptoms (**dyspnea**, **cough**, **sputum production**, and/or **exacerbations**) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often **progressive airflow obstruction**. A diagnosis of COPD is confirmed by post-bronchodilator spirometry showing FEV1/FVC <0.70.[1] COPD is the third leading cause of death worldwide, affecting an estimated **392 million people** globally (**10.3% prevalence** in adults aged **30–79**).[2] In value-based care settings, COPD presents a critical **documentation challenge**: emphysema identified on CT imaging frequently **precedes the decline in pulmonary function tests (PFTs)** used for formal diagnosis, and chronic bronchitis in at-risk populations (smokers, occupational exposures) is commonly under-recognized and under-coded.[1]

ICD-10 Codes[3]

Primary COPD codes (**J44.x series**): **J44.0** (COPD with acute lower respiratory infection), **J44.1** (COPD with acute exacerbation), **J44.89** (other specified COPD), **J44.9** (COPD, unspecified). **Note**: **J44.8** is not a valid standalone code; use **J44.81** (bronchiolitis obliterans and bronchiolitis obliterans syndrome) or **J44.89** (other specified COPD) for specificity.

Emphysema codes (**J43.x series**): **J43.0** (unilateral/MacLeod syndrome), **J43.1** (panlobular), **J43.2** (centrilobular), **J43.8** (other), **J43.9** (unspecified).

Chronic bronchitis codes: **J41.0** (simple chronic bronchitis), **J41.1** (mucopurulent chronic bronchitis), **J41.8** (mixed simple and mucopurulent chronic bronchitis), **J42** (unspecified chronic bronchitis).

Complication codes: **J96.x** (respiratory failure; sequence as secondary, specifying acute [**J96.0x**], chronic [**J96.1x**], or acute-on-chronic [**J96.2x**], and whether with hypoxia or hypercapnia).

Specificity note: All COPD-spectrum codes map to the same **HCC 280** (HCC v28), but accurate documentation requires the most specific code matching the patient's clinical presentation.[1] Document emphysema subtype when identified on imaging (**J43.1**, **J43.2**) rather than defaulting to unspecified (**J43.9**). Code chronic bronchitis (**J41.0**, **J41.1**, **J41.8**, or **J42**) when productive cough for 3 or more months in 2 consecutive years is documented.[1]

AAVBC PERSPECTIVE

*COPD is underrecognized and often missed in its **earliest stages**. Clinicians should act on early signals, including risk factors, chronic productive cough of at least 3 months, or CT evidence of emphysema, by documenting and coding these findings as they appear **rather than waiting for PFT confirmed decline**. Radiologic findings of emphysema typically precede spirometry or PFT findings of COPD. Early, accurate documentation in at risk patients enables timely intervention and better outcomes.*

HCC/RAF V28 Mapping

DIAGNOSIS CATEGORY	ICD-10 SERIES	V28 HCC[3]	RAF VALUE*	CLINICAL DOCUMENTATION REQUIREMENT
COPD (all subtypes)	**J44.x:** J44.0, J44.1, J44.81, J44.89, J44.9	**HCC 280**	0.319	Post-bronchodilator spirometry **FEV1/FVC <0.70** or **CT-identified emphysema** with clinical context.[1] Active diagnosis with MEAT documented by 12/31 of payment year
Emphysema (all subtypes)	**J43.x**: J43.0, J43.1, J43.2, J43.8, J43.9	**HCC 280**	0.319	CT imaging findings documenting emphysema subtype (panlobular, centrilobular). Document even if PFTs remain within normal limits; GOLD 2026 recognizes pre-COPD/PRISm state[1]
Chronic Bronchitis	**J41.x, J42**	**HCC 280**	0.319	Clinical criteria: **productive cough ≥3 months in 2 consecutive years**. Document in at-risk populations. When COPD criteria are also met, assign a **J44.x code concurrently** to capture risk adjustment
COPD with acute exacerbation	**J44.1**	**HCC 280**	0.319	Acute worsening of respiratory symptoms requiring change in therapy. Document severity per Rome Proposal criteria.[4] Carries Pharmacotherapy Management of COPD Exacerbation (PCE) quality measure implications (CMS eCQM CMS137)
COPD with acute lower respiratory infection	**J44.0**	**HCC 280**	0.319	Use additional code to identify the specific infection. **Distinguish from J44.1** (exacerbation without infection)

ABBREVIATIONS: COPD = Chronic Obstructive Pulmonary Disease; CT = Computed Tomography; FEV1 = Forced Expiratory Volume in 1 second; FVC = Forced Vital Capacity; HCC = Hierarchical Condition Category; MEAT = Monitor, Evaluate, Assess, Treat; PCE = Pharmacotherapy Management of COPD Exacerbation; PFT = Pulmonary Function Test; PRISm = Preserved Ratio Impaired Spirometry; RAF = Risk Adjustment Factor
**RAF values represent the Community Non-Dual Eligible Aged (CNA) coefficient from the 2024 CMS-HCC model; values vary across patient populations based on eligibility and care setting*

Risk-Adjusted Care Resources per Patient/Year[3,5]
Risk-adjusted care resource allocation — MA base rate × RAF coefficient for HCC280: 0.319

COPD/EMPHYSEMA/CHRONIC BRONCHITIS
~$3,318
HCC 280 · RAF 0.319

RAF values represent the Community Non-Dual Eligible Aged (CNA) coefficient from the 2024 CMS-HCC model; values vary across patient populations based on eligibility and care setting

Prevalence (U.S.)

Approximately **16 million U.S. adults** have been diagnosed with COPD,[6] though true prevalence is substantially higher due to **underdiagnosis**; spirometry-based estimates suggest **as many as 29 million people may be affected**.[7] The most recent NCHS data (2023 NHIS) report an age-adjusted diagnosed **prevalence of 3.8%** among adults aged 18 and older,[8] while BRFSS data from 2011 to 2021 show a stable age-standardized prevalence of approximately 6.0%, with significantly higher rates among adults aged 65 and older, women, ever-smokers, and those living in rural areas.[9] Chronic lower respiratory diseases, composed predominantly of COPD, ranked as the **fifth leading cause of death** in the United States in 2023.[10] COPD is also the **third leading cause of 30-day readmissions among U.S. adults**;[11] among Medicare fee-for-service beneficiaries, the 30-day readmission rate following COPD hospitalization is approximately **19 to 20%**,[12] with 1-year readmission rates reaching **64.2%**.[13] In 2019, COPD-attributable direct medical costs totaled an **estimated $31.3 billion** nationally, of which **$10.8 billion** was borne by Medicare, and costs are projected to reach **$60.5 billion by 2029**.[14] Among Medicare beneficiaries with recent exacerbations, adjusted all-cause annual costs range from **$24,000 to $26,600 per patient**, with those experiencing severe exacerbations incurring 6 to 9% higher costs than non-exacerbators.[15]

2 RECOGNITION AND DIAGNOSIS

Airway Function Tests and Diagnostic Thresholds

Respiratory Function Tests

TEST/TOOL	WHAT IT MEASURES	SIGNIFICANCE IN COPD
FEV_1 (Forced Expiratory Volume in 1 second)	Volume of air forcefully exhaled in the first second	Reduced in obstructive disease; used to grade COPD severity (**GOLD 1–4**)
FVC (Forced Vital Capacity)	Total volume of air forcefully exhaled after maximal inspiration	May be reduced due to air trapping; denominator in the FEV_1/FVC ratio

TEST/TOOL	WHAT IT MEASURES	SIGNIFICANCE IN COPD
FEV_1/FVC Ratio	Proportion of vital capacity expelled in the first second	Post-bronchodilator 0.7 confirms persistent airflow limitation — the defining criterion for COPD diagnosis
Peak Expiratory Flow (PEF)	Maximum speed of expiration	Effort-dependent; less reliable than spirometry for COPD diagnosis but useful for screening
DLCO (Diffusing Capacity for CO)	Gas exchange efficiency across the alveolar-capillary membrane	Reduced in emphysema; differentiates emphysema-predominant from airway-predominant COPD
TLC (Total Lung Capacity)	Total volume of air in the lungs after maximal inspiration	Elevated in hyperinflation/air trapping
RV (Residual Volume)	Volume of air remaining after maximal exhalation	Increased in COPD due to air trapping; RV/TLC ratio reflects gas trapping severity
IC (Inspiratory Capacity)	Maximum volume inhaled from end-tidal expiration	Reduced with dynamic hyperinflation; IC/TLC ratio predicts exercise limitation and mortality
mMRC Dyspnea Scale (Grade 0–4)	Questionnaire (see below); Severity of breathlessness during daily activities	mMRC **≥2** classifies patients as "**more symptomatic**" (Group B/E); measures **dyspnea only**, not comprehensive symptoms
CAAT™ (formerly CAT; Score 0–40)	Questionnaire (see below); Comprehensive COPD symptom burden (cough, sputum, chest tightness, breathlessness, activity limitation, confidence, sleep, energy)	CAAT™ **≥10** classifies patients as "**more symptomatic**" (Group B/E); GOLD-preferred tool because it captures the full range of COPD symptoms **beyond dyspnea alone**

ABBREVIATIONS: *FEV_1 = Forced Expiratory Volume in 1 Second; GOLD = Global Initiative for Chronic Obstructive Lung Disease; FVC = Forced Vital Capacity; COPD = Chronic Obstructive Pulmonary Disease; PEF = Peak Expiratory Flow; DLCO = Diffusing Capacity of the Lungs for Carbon Monoxide; CO = Carbon Monoxide; TLC = Total Lung Capacity; RV = Residual Volume; IC = Inspiratory Capacity; mMRC = Modified Medical Research Council; CAAT™ = COPD Assessment and Audit Tool; CAT = COPD Assessment Test*

Modified Medical Research Council (mMRC) Dyspnea Scale (Questionnaire)

GRADE	DESCRIPTION OF BREATHLESSNESS
0	I only get breathless with strenuous exercise
1	I get short of breath when hurrying on level ground or walking up a slight hill

GRADE	DESCRIPTION OF BREATHLESSNESS
2	On level ground, I walk slower than people of the same age because of breathlessness, or have to stop for breath when walking at my own pace
3	I stop for breath after walking about 100 yards [91 meters] or after a few minutes on level ground
4	I am too breathless to leave the house or I am breathless when dressing

Chronic Airways Assessment Test (CAAT™; Questionnaire)

QUESTIONNAIRE PROMPT - LOW (0)	QUESTIONNAIRE PROMPT - HIGH (5)	PATIENT RESPONSE
I never cough	I cough all the time	0-5
I have no phlegm/mucus in my chest at all	My chest is completely full of phlegm/mucus	0-5
My chest does not feel tight at all	My chest feels very tight	0-5
When I walk up a hill or one flight of stairs I am not breathless	When I walk up a hill or one flight of stairs I am very breathless	0-5
I am not limited doing any activities at home	I am limited doing any activities at home	0-5
I am confident leaving my home despite my lung condition	I am not at all confident leaving my home because of my lung condition	0-5
I sleep soundly	I don’t sleep soundly because of my lung condition	0-5
I have lots of energy	I have no energy at all	0-5

Gold 2026 COPD Classifications

GOLD (Global Initiative for Chronic Obstructive Lung Disease) is the internationally recognized framework for COPD classification, updated annually.[1] GOLD grades airflow limitation by **post-BD FEV1 % predicted** (Grades 1 to 4) and classifies patients by **symptom burden and exacerbation history** (Groups A, B, E). Together, these two axes guide initial therapy selection and escalation decisions.[1]

CATEGORY	MEASURE	THRESHOLD	CLINICAL NOTE
Confirm Diagnosis[1]	Post-BD spirometry	**FEV_1/FVC <0.70** post-BD	Pre-BD spirometry can exclude COPD (if FEV1/FVC **≥0.70**) but cannot confirm it; post-BD testing is mandatory for diagnosis. If pre-BD ratio 0.6–0.8, repeat on a separate occasion
Spirometric Severity[1]	**GOLD 1** (Mild)	**FEV_1 ≥80% predicted**	Airflow limitation present but patients often unaware; **80%** of GOLD 1 patients have FEV1/FVC values **between 0.6 and 0.7**, close to the diagnostic threshold
Spirometric Severity[1]	**GOLD 2** (Moderate)	**FEV_1 50–79% predicted**	Dyspnea on exertion; most individuals seek care for the first time at this stage
Spirometric Severity[1]	**GOLD 3** (Severe)	**FEV_1 30–49% predicted**	Increased dyspnea, exacerbation frequency, and reduced exercise capacity with significant impact on quality of life
Spirometric Severity[1]	**GOLD 4** (Very Severe)	**FEV_1 <30% predicted**	Respiratory failure risk; quality of life markedly impaired; Advance care planning discussion warranted alongside ongoing management
Imaging[1]	CT chest	Emphysema visible on CT	Supports **J43.x** documentation even when spirometry is preserved (pre-COPD/PRISm). GOLD 2026 recommends spirometry when incidental imaging abnormalities consistent with airways disease are found
Gold A/B/E Group exacerbation history	A	mMRC 0-1 CAAT™ 10	Low symptom burden, low exacerbation risk
Gold A/B/E Group exacerbation history	A	mMRC 0-1 CAAT™ 10	Low symptom burden, low exacerbation risk
Gold A/B/E Group exacerbation history	B	mMRC ≥2 CAAT™ ≥10	Higher symptom burden, low exacerbation risk
Gold A/B/E Group exacerbation history	B	mMRC ≥2 CAAT™ ≥10	Higher symptom burden, low exacerbation risk

CATEGORY	MEASURE	THRESHOLD	CLINICAL NOTE
Gold A/B/E Group exacerbation history	E	Any Any	Exacerbation history drives classification regardless of symptom score
Gold A/B/E Group exacerbation history	E	Any Any	Exacerbation history drives classification regardless of symptom score
Exacerbation Severity[4]	Mild	Dyspnea VAS 5, RR 24, HR 95, SpO2 ≥92% (or change =3%), CRP 10 mg/L	All variables below thresholds; Manageable in outpatient setting with increased SABA use
Exacerbation Severity[4]	Moderate	**≥3 of**: Dyspnea VAS ≥5, RR ≥24, HR ≥95, SpO2 92% or change >3%, CRP ≥10 mg/L	Three or more variables must exceed thresholds to classify as moderate. Requires systemic corticosteroids and/or antibiotics
Exacerbation Severity[4]	Severe	Moderate criteria PLUS PaO2 =60 mmHg and/or PaCO2 >45 mmHg with pH 7.35	Requires hospitalization; ABG at point of care; **Rome classification** correlates with ICU admission, MV need, and 1-year mortality (HR 1.99 for severe vs. mild)

ABBREVIATIONS: *ABG = Arterial Blood Gas; BD = Bronchodilator; CAT = COPD Assessment Test; COPD = Chronic Obstructive Pulmonary Disease; CRP = C-Reactive Protein; CT = Computed Tomography; FEV1 = Forced Expiratory Volume in 1 Second; FVC = Forced Vital Capacity; GOLD = Global Initiative for Chronic Obstructive Lung Disease; HR (clinical) = Heart Rate; HR (statistical) = Hazard Ratio; ICU = Intensive Care Unit; mMRC = Modified Medical Research Council Dyspnea Scale; MV = Mechanical Ventilation; PaCO2 = Partial Pressure of Carbon Dioxide; PaO2 = Partial Pressure of Oxygen; PRISm = Preserved Ratio Impaired Spirometry; RR = Respiratory Rate; SABA = Short-Acting Beta2-Agonist; SpO2 = Oxygen Saturation; VAS = Visual Analog Scale*

Medicare Screenings

NOTE: All screenings are covered for Medicare patients when deemed medically necessary except for spirometry screening for asymptomatic adults

TEST	FREQUENCY	CPT CODE	WHAT IT MEASURES
Spirometry (diagnostic)	No specific limit; repeat when clinically indicated	**94010**	FVC, FEV1, and FEV1/FVC ratio; confirms airflow obstruction; GOLD 2026 defines obstruction as **FEV1/FVC <0.70**[1,16]

TEST	FREQUENCY	CPT CODE	WHAT IT MEASURES
Bronchodilator responsiveness	At diagnosis and as clinically indicated	**94060**	Pre- and post-bronchodilator spirometry; Pre-BD can exclude COPD; post-BD FEV1/FVC <0.70 confirms diagnosis; Degree of reversibility no longer recommended to guide therapy[1,17]
Plethysmography (lung volumes)	As clinically indicated	**94726**	TLC, RV, FRC; Evaluates hyperinflation and air trapping. **RV/TLC >0.35** indicates air trapping[18]
Diffusing capacity (DLCO)	As clinically indicated	**94729**	Gas exchange efficiency; Reduced DLCO (60% predicted) associated with increased symptoms, exacerbation risk, and mortality independent of FEV1;[1,19] **Low DLCO in smokers without obstruction** signals increased risk of developing COPD
Spirometry (screening in asymptomatic adults)*	N/A	N/A	USPSTF Grade D recommendation: screening asymptomatic adults has no net benefit; Case-finding in symptomatic patients with risk factors is appropriate[1,20]
Alpha 1 antitrypsin deficiency (AATD) screening	Recommended for all diagnosed COPD patients[1]	**82103**	**Serum AAT protein level**; normal is ≥1.1 g/L with normal CRP;[21] Level <1.1 g/L or strong clinical suspicion warrants **SERPINA1 genotyping;**[21,22] Concentration <20% of normal is highly suggestive of homozygous deficiency[1]

ABBREVIATIONS: *FVC = Forced Vital Capacity; FEV1 = Forced Expiratory Volume in 1 Second; GOLD = Global Initiative for Chronic Obstructive Lung Disease; BD = Bronchodilator; COPD = Chronic Obstructive Pulmonary Disease; TLC = Total Lung Capacity; RV = Residual Volume; FRC = Functional Residual Capacity; DLCO = Diffusing Capacity of the Lungs for Carbon Monoxide; USPSTF = U.S. Preventive Services Task Force; CPT = Current Procedural Terminology*

Subtle Early Signs in Adults

SIGN/SYMPTOM	CLINICAL SIGNIFICANCE FOR COPD RECOGNITION
Chronic productive cough dismissed as "smoker's cough"	Productive cough ≥3 months in 2 consecutive yrs meets chronic bronchitis criteria (**J42/J41.x**) when other causes are excluded;[1] Document **as a distinct diagnosis**, **not a symptom**
Progressive exertional dyspnea attributed to aging or deconditioning	Chronic dyspnea is the most characteristic symptom of COPD;[1] Patients may underreport symptoms by **restricting activity to avoid dyspnea**.[7] Distinguish from cardiac dyspnea (orthopnea, PND); Assess with **mMRC/CAAT** and spirometry[1,7]

SIGN/SYMPTOM	CLINICAL SIGNIFICANCE FOR COPD RECOGNITION
Recurrent "chest colds" or lower respiratory tract infections	**Recurrent lower respiratory tract infections** are a GOLD 2026 clinical indicator for considering a COPD diagnosis and performing spirometry[1]
CT-identified emphysema as incidental finding	GOLD 2026 recommends spirometry when incidental imaging abnormalities consistent with airways disorders are found;[1] Document **J43.x with subtype** even if spirometry is normal
Barrel chest with decreased breath sounds on exam	Physical signs of airflow obstruction are **usually not present until significant impairment has occurred**; detection has relatively low sensitivity and specificity;[1] Do not rely on **absence of exam** findings to **exclude COPD**
Weight loss and muscle wasting in a known smoker	Weight loss, muscle mass loss, and anorexia are common in **severe/very severe COPD** and carry prognostic importance, but can also signal TB or lung cancer and should always be investigated[1]

ABBREVIATIONS: *COPD = Chronic Obstructive Pulmonary Disease; PND = Paroxysmal Nocturnal Dyspnea; mMRC = Modified Medical Research Council Dyspnea Scale; CAAT™ = COPD Assessment and Audit Tool; GOLD = Global Initiative for Chronic Obstructive Lung Disease; CT = Computed Tomography; TB = Tuberculosis*

Risk Factors

FACTOR	RISK SIGNAL	EVIDENCE SUMMARY	CLINICAL IMPLICATION
Current smoking	OR 3.2 (95% CI 2.5-4.0)[2]	Global meta-analysis, 162 studies;[2] US COPD prevalence: 15.2% current smokers vs 2.8% never-smokers;[25] >70% of COPD cases in high-income countries attributable to smoking[1]	Document pack-years; counsel cessation each visit; spirometry if symptomatic
Former smoking	OR 2.3 (95% CI 2.0-2.5) (ever-smoker)[2]	Risk persists after cessation and rises with pack-years;[1] US BRFSS COPD prevalence: **7.6% in former smokers**[25]	Document pack-years + quit date; spirometry if symptomatic and **≥20 pack-years**
>20 pack-years cumulative	Significant independent predictor	Most COPD studies require minimum 10 pack-year exposure; even 10 pack-years increases 5-year COPD risk in middle-aged adults[1]	Heightened suspicion; review available imaging for emphysema
Occupational dust/fumes exposure	PAF 19.2% overall; 31.1% among never-smokers (US)[26]	ATS/ERS: occupational PAF 14%;[27] US NHIS 2012-2018: **27.3% of worker COPD attributable to occupation**[28]	Document job/exposure hx; consider J43.x/J42 in symptomatic never-smokers

FACTOR	RISK SIGNAL	EVIDENCE SUMMARY	CLINICAL IMPLICATION
Biomass fuel exposure	OR 1.4 (95% CI 1.2-1.7)[2]	Primarily relevant in LMICs but applicable to US immigrant populations[1]	Document indoor cooking/ heating fuel hx; recognize non-smoking COPD phenotype
Childhood respiratory infections	OR 2.23 (95% CI 1.63-3.07)[29]	Childhood serious respiratory infections/pneumonia/bronchitis associated with adult COPD;[29] Early disadvantage may confer COPD risk comparable to adult smoking[1]	Document childhood resp hx; lower threshold for spirometry in older at-risk adults
History of tuberculosis	OR 2.46 (95% CI 1.95-3.10)[30]	Post-TB airflow limitation from structural damage (cavitation, fibrosis, bronchiectasis) may **mimic or coexist with COPD**;[1] ICS use may increase TB reactivation risk[1]	Evaluate spirometry for fixed obstruction; document as COPD if criteria met; use ICS with caution
Low BMI (≤18.5 kg/m^2)	OR 2.2 (95% CI 1.7-2.7)	Pooled global meta-analysis;[2] Weight loss and muscle wasting carry prognostic importance in severe COPD but may also signal TB or lung cancer[1]	Screen for COPD-related **cachexia**; assess nutritional status and refer for pulmonary rehabilitation
Alpha-1 antitrypsin deficiency (AATD)	PiZZ: 1/3,000-1/5,000 North America;[22] 0.09% of Medicare COPD pts diagnosed[3]	**Best-established genetic COPD risk;** SERPINA1 variants;[1] PiZZ → early basal panlobular emphysema; PiMZ OR 5.18, rising to 10.65 in ever-smokers[32]	Test all COPD pts for AATD;[1] code E88.01 + J43.x/J44.x if confirmed; AAT <1.1 g/L → genotype;[21] refer + family screen[1]

ABBREVIATIONS: *OR = Odds Ratio; CI = Confidence Interval; COPD = Chronic Obstructive Pulmonary Disease; BRFSS = Behavioral Risk Factor Surveillance System; PAF = Population Attributable Fraction; ATS = American Thoracic Society; ERS = European Respiratory Society; NHIS = National Health Interview Survey; LMIC = Low- and Middle-Income Countries; TB = Tuberculosis; ICS = Inhaled Corticosteroid; BMI = Body Mass Index; AATD = Alpha-1 Antitrypsin Deficiency; SERPINA1 = Serine Protease Inhibitor, Group A, Member 1; PiZZ = Protease Inhibitor Genotype ZZ (Homozygous); PiMZ = Protease Inhibitor Genotype MZ (Heterozygous); AAT = Alpha-1 Antitrypsin*

RED FLAGS — IMMEDIATE ED TRANSFER

These findings indicate **life-threatening decompensation** requiring emergent evaluation and stabilization:

- **Severe dyspnea at rest** unrelieved by rescue bronchodilators: assess for respiratory failure, pneumothorax, or pulmonary embolism
- **Altered mental status** (confusion, lethargy, agitation): suggests hypercapnia or hypoxemia; emergent ABG required
- **SpO2 <90% on room** air or >3% drop from baseline despite supplemental O2: may require non-invasive ventilation or intubation
- **Hemodynamic instability** (HR >110, SBP <90 mmHg): indicates cardiovascular compromise; emergent resuscitation
- **Failure to respond** to initial outpatient exacerbation therapy within 48 to 72 hours: reassess for pneumonia, PE, or acute heart failure

RED FLAGS — CARDIOVASCULAR OVERLAP REQUIRING URGENT EVALUATION

COPD exacerbations **independently increase cardiovascular event risk**. CV events are most frequent in the first 30 days following exacerbation and remain elevated for up to 1 year.

- **New or worsening peripheral edema with respiratory distress**: evaluate for cor pulmonale or acute decompensated heart failure complicating COPD; urgent cardiology and pulmonology consultation
- **Chest pain during exacerbation**: rule out MI, PE, and pneumothorax before attributing to musculoskeletal or pleuritic cause; troponin, ECG, and CT angiography as indicated

RED FLAGS — SIGNS SUGGESTING ALTERNATIVE OR COEXISTING DIAGNOSIS

These findings should prompt evaluation beyond COPD exacerbation alone:

- **Hemoptysis** (beyond blood-streaked sputum): evaluate for lung malignancy, TB, or bronchiectasis; chest CT and sputum studies indicated
- **Unilateral leg swelling with acute dyspnea**: high suspicion for PE; COPD patients have 1.5x baseline PE risk; apply Wells criteria and obtain CT angiography
- **Rapid unexplained weight loss** (>5% over 6 to 12 months): screen for lung cancer, TB, or COPD-related cachexia; chest CT and nutritional assessment



- Limited awareness or underreporting of respiratory symptoms
- Activity modification that masks exertional dyspnea
- Early disease perceived as normal aging or low impact
- Normalization of chronic cough or sputum (especially in smokers)
- Comorbid conditions obscuring respiratory decline

- Limited access to diagnostic testing (spirometry)
- Inequities in healthcare access across regions and populations
- Delays in testing due to capacity or referral bottlenecks
- Gaps in respiratory care infrastructure and workforce
- Limited proactive screening of at-risk populations

- Gaps in recognition of early COPD and risk profiles
- Underuse or misinterpretation of spirometry
- Symptom-based management without objective confirmation
- Missed opportunities for early case-finding and coding
- Delayed diagnosis until pulmonary function test thresholds are met, at which point disease progression may already be advanced and less responsive to intervention

Clues to Dig Deeper

- **Incidental emphysema on CT for other indications →** Document **J43.x** with subtype; order spirometry for baseline. CT emphysema can precede spirometric obstruction by years; GOLD 2026 recognizes this as "**pre-COPD**"[1]
- **Persistent productive cough in a current/former smoker →** Productive cough ≥3 months in 2 consecutive years meets chronic bronchitis criteria; document **J42/J41.x** as a diagnosis, **not a symptom**[1]
- **Rescue inhaler prescriptions without a coded COPD diagnosis →** Review problem list; ongoing bronchodilator use requires a documented underlying condition. Undiagnosed COPD carries 15.5x higher exacerbation risk[1]
- **FEV1 declining >**40 **mL/year on serial spirometry →** Accelerated progression; reassess GOLD group, escalate therapy, and document trajectory[1,7]

- **=2 antibiotic courses/year for "bronchitis" or "pneumonia" →** Recurrent lower respiratory infections are a GOLD 2026 indicator for spirometric evaluation[1]
- **Dyspnea disproportionate to cardiac findings →** HF prevalence in COPD is 20 to 30% and frequently underdiagnosed; evaluate with BNP, echocardiography, and spirometry[1,33]
- **No AATD testing on record →** All COPD patients should be tested (ATS/ERS).[1,34] Only 5.6% of newly diagnosed US COPD patients were tested (2012 to 2021);[35] ~90% of cases remain undiagnosed with **5 to 7 year diagnostic delay**.[21,36] Serum AAT <1.1 g/L warrants **genotyping**

Common Oversights

- **Dyspnea dismissed as deconditioning or aging →** 71% of US adults with spirometric obstruction had no prior COPD diagnosis (NHANES 2007 to 2012);[1] consider whether spirometry has been performed
- **Acute dyspnea attributed to a single cause →** COPD and HF co-occur in up to 30% of patients; consider whether both conditions are active before attributing to one diagnosis[1,33]
- **Bronchodilator reversibility not followed up →** Coexistent asthma may affect 15 to 45% of obstructive lung disease patients with worse outcomes; evaluate if history of childhood asthma, atopy, or wheezing[1,37]
- **Resting SpO2 as sole oxygenation measure →** Patients may desaturate significantly with exertion or sleep despite acceptable resting values; consider 6MWT or **nocturnal oximetry**[1]
- **AATD not considered in any COPD patient →** Barriers include inadequate physician knowledge and therapeutic nihilism; augmentation therapy is FDA-approved. Testing disparities: older, non-White, and male COPD patients have lower odds of being tested[35,36]

Key Differentials in Elderly

PRESENTATION	DIFFERENTIAL	KEY TESTS
Progressive exertional dyspnea + smoking/ exposure history	**Asthma**; HF (HFrEF/HFpEF); deconditioning; pulmonary hypertension; restrictive lung disease	Post-BD spirometry (FEV1/FVC <0.70 confirms COPD; ≥12% and ≥200 mL reversibility suggests asthma);[1,17] BNP/NT-proBNP (≥100/≥300 pg/mL suggests HF);[33,38] echocardiography; DLCO (low in emphysema, normal in asthma)[1,39]

PRESENTATION	DIFFERENTIAL	KEY TESTS
Chronic productive cough ≥3 months/year x 2 years	**Bronchiectasis**; chronic bronchitis (**J42/J41.x**); lung cancer; GERD; ACE inhibitor cough	CT chest (bronchial dilation, airway-to-artery ratio **≥1.0** = **bronchiectasis**; emphysema subtypes);[40,41] sputum culture if purulent; spirometry; medication review
Acute worsening dyspnea + cough/sputum in known COPD	COPD exacerbation; **PE** (16 to 25% prevalence in unexplained exacerbations);[42,43] pneumonia; acute HF; pneumothorax	CXR; CBC, CRP, procalcitonin; D-dimer if PE suspected;[44] CTPA if D-dimer elevated; BNP; ECG (rule out MI, arrhythmia); Rome Proposal severity criteria[4]
Dyspnea + peripheral edema + JVD in COPD patient	Cor pulmonale/right HF; COPD-HF overlap (HF prevalence 20 to 30% in COPD);[18,33] renal disease; hepatic disease	Echocardiography (RV function, PASP); BNP/NT-proBNP; CMP; spirometry in compensated state to avoid misdiagnosis[33]
Eosinophilia + variable symptoms + atopy history in smoker	Asthma-COPD overlap (15 to 45% of obstructive lung disease);[37] eosinophilic COPD; allergic bronchopulmonary aspergillosis	Blood eosinophils (**≥300 cells/mcL**); [1,45] FeNO (low DLCO favors COPD over asthma);[39] total IgE; spirometry with BD response; allergy testing if indicated
Incidental emphysema on CT, spirometry normal	Pre-COPD/PRISm; normal aging; **AATD** (1 in 3,000 to 5,000 in North America);[21] cystic lung disease	Post-BD spirometry (may be normal); [1] serum AAT level (≥1.1 g/L warrants genotyping);[21] serial spirometry annually; document **J43.x** with subtype even if PFTs normal[1]

ABBREVIATIONS: *AAT = Alpha-1 Antitrypsin; AATD = Alpha-1 Antitrypsin Deficiency; ACE = Angiotensin-Converting Enzyme; BD = Bronchodilator; BNP = B-type Natriuretic Peptide; CBC = Complete Blood Count; CMP = Comprehensive Metabolic Panel; COPD = Chronic Obstructive Pulmonary Disease; CRP = C-Reactive Protein; CT = Computed Tomography; CTPA = CT Pulmonary Angiography; CXR = Chest X-ray; DLCO = Diffusing Capacity of the Lungs for Carbon Monoxide; ECG = Electrocardiogram; FEV1 = Forced Expiratory Volume in 1 Second; FeNO = Fractional Exhaled Nitric Oxide; FVC = Forced Vital Capacity; GERD = Gastroesophageal Reflux Disease; HF = Heart Failure; HFpEF = Heart Failure with Preserved Ejection Fraction; HFrEF = Heart Failure with Reduced Ejection Fraction; IgE = Immunoglobulin E; JVD = Jugular Venous Distension; MI = Myocardial Infarction; NT-proBNP = N-terminal Pro-B-type Natriuretic Peptide; PASP = Pulmonary Artery Systolic Pressure; PE = Pulmonary Embolism; PFT = Pulmonary Function Test; PRISm = Preserved Ratio Impaired Spirometry; RV = Right Ventricle*

Comorbidity Screening

CONDITION	PREVALENCE IN THIS POPULATION	SCREENING APPROACH
Heart failure	**20 to 30%**; HFrEF and HFpEF occur with similar frequency (~10% each); annual incidence 3 to 4%.[1] HF is frequently underdiagnosed and is an independent predictor of all-cause mortality[1,33]	BNP/NT-proBNP (**NPV 0.80 to 0.98** to exclude LV dysfunction in stable COPD and during exacerbations);[1] echocardiography if abnormal; selective beta1-blockers are safe and recommended in COPD patients with HF[1,38]
Coronary artery disease	**10 to 20%**; associated with increased morbidity and mortality; [1] CV event risk elevated during and for ≥1 year post-exacerbation (MI, stroke, arrhythmia, unstable angina)[1,46]	**Lipid panel**; CV risk calculator (NHLBI); screen with hs-troponin at COPD diagnosis and at unexplained symptom change (29 to 39% of stable COPD patients have elevated hs-troponin);[1] ECG; treat per cardiology guidelines[1]
Atrial fibrillation	OR 1.39 (95% CI 1.34 to 1.44) vs. controls;[47] prevalence increases with GOLD severity; AF more prevalent in COPD-OSA overlap syndrome[48]	Pulse check at every visit; ECG if irregular rhythm detected; review medications (high-dose beta2-agonists and theophylline may worsen AF);[1] **cardioselective beta-blockers are safe in COPD**[1]
Type 2 diabetes mellitus	**~20%** of COPD patients;[1] up to 27–30% in some cohorts;[49] T2DM increases morbidity, mortality, and complicates COPD management	HbA1c and fasting glucose if not tested within 1 year;[1] monitor glucose during systemic corticosteroid courses (hyperglycemia worsens infection risk); high-dose ICS associated with worsening DM control[1]
Depression/ Anxiety	~34% prevalence for anxiety alone and combined anxiety/ depression; depression alone more common in men (61% vs. 39%);[1] Pooled global depression prevalence 34.5% (OR 3.53 vs. non-COPD)[50]	PHQ-2 (score **≥3 warrants further evaluation**) for depression; GAD-2 (score ≥3) for anxiety;[1] untreated depression independently predicts exacerbations, **non-adherence**, and 30-day readmission[1,51]
Osteoporosis	Prevalence **up to 30% in women** and 18% in men with COPD;[1] 19.9% of COPD patients had ≥1 osteoporosis-related event vs. 12.9% of controls;[52] Low BMD and fractures common even after adjusting for steroid use[1]	DEXA scan if ICS use, systemic steroid history, or low BMI; chest CT can help identify low BMD; [1] high-dose ICS associated with dose-dependent osteoporosis risk (RR 1.52);[52] avoid repeated systemic corticosteroid courses when possible[1]

CONDITION	PREVALENCE IN THIS POPULATION	SCREENING APPROACH
Obstructive sleep apnea	OSA affects 9–26% US adults;[1] COPD-OSA overlap prevalence ~28% globally;[53] Overlap patients have worse prognosis than either condition alone[1]	**STOP-BANG questionnaire** if obesity, snoring, daytime somnolence, or hypertension;[1] **polysomnography** if clinical suspicion; CPAP reduces all-cause hospitalizations, ER visits, exacerbations, and mortality in overlap syndrome[1]
Lung cancer	COPD is an independent risk factor for lung cancer (HR 2.2 to 10 depending on severity);[1] emphysema on CT independently increases risk beyond airflow obstruction alone;[1] In the NLST, 1.9% of LDCT-screened participants were diagnosed with lung cancer at baseline[54]	Annual LDCT if age 50–80 and ≥20 pack-year smoking history per USPSTF 2021[55] and ACS 2023[56] criteria; COPD and emphysema are additional risk factors in validated screening models (PLCOm2012);[56] leverage lung cancer screening CT for simultaneous COPD case-finding[1]
Bronchiectasis	20 to 69% on CT; typically cylindrical, bilateral, lower-lobe dominant.[1] Associated with increased exacerbation frequency, pneumonia risk, and mortality[1]	CT chest if persistent purulent sputum or recurrent infections; sputum culture to guide antibiotic therapy;[1] evaluate ICS use carefully (increased pneumonia and NTM risk); consider macrolide therapy for exacerbation reduction[1]
GERD	17 to 78% in COPD patients vs. ~18% in controls;[57] prevalence higher with severe airflow obstruction;[58] Independent risk factor for COPD exacerbations[1]	Symptom assessment; empiric PPI trial may improve symptoms and decrease exacerbation risk;[1] weight loss if obese; avoid late-night meals; semi-recumbent sleeping posture; surgical fundoplication if conservative therapy fails[1]

ABBREVIATIONS: *HFrEF = Heart Failure with Reduced Ejection Fraction; HFpEF = Heart Failure with Preserved Ejection Fraction; HF = Heart Failure; BNP = B-type Natriuretic Peptide; NT-proBNP = N-terminal Pro-B-type Natriuretic Peptide; NPV = Negative Predictive Value; LV = Left Ventricular; COPD = Chronic Obstructive Pulmonary Disease; CV = Cardiovascular; MI = Myocardial Infarction; NHLBI = National Heart, Lung, and Blood Institute; hs-troponin = High-Sensitivity Troponin; ECG = Electrocardiogram; OR = Odds Ratio; CI = Confidence Interval; GOLD = Global Initiative for Chronic Obstructive Lung Disease; AF = Atrial Fibrillation; OSA = Obstructive Sleep Apnea; T2DM = Type 2 Diabetes Mellitus; HbA1c = Hemoglobin A1c; ICS = Inhaled Corticosteroid; DM = Diabetes Mellitus; PHQ-2 = Patient Health Questionnaire 2-item; GAD-2 = Generalized Anxiety Disorder 2-item; BMD = Bone Mineral Density; BMI = Body Mass Index; CT = Computed Tomography; RR = Risk Ratio; DEXA = Dual-Energy X-ray Absorptiometry; CPAP = Continuous Positive Airway Pressure; ER = Emergency Room; HR = Hazard Ratio; NLST = National Lung Screening Trial; LDCT = Low-Dose Computed Tomography; USPSTF = U.S. Preventive Services Task Force; ACS = American Cancer Society; PLCOm2012 = Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Model 2012; NTM = Nontuberculous Mycobacteria; GERD = Gastroesophageal Reflux Disease; PPI = Proton Pump Inhibitor*

GOLD 2026 Group Classification by Frailty Status

GOLD GROUP	CRITERIA	ROBUST	PRE-FRAIL	FRAIL
A	mMRC 0–1 **AND** CAT <10; 0–1 moderate exacerbations (no hospitalization)	LAMA or LABA monotherapy; LAMA preferred for greater exacerbation reduction (RR 0.81, LAMA vs. LABA);[1,59] Encourage exercise maintenance	LAMA preferred over LABA (greater exacerbation reduction, fewer adverse events);[60] Assess fall risk; frailty screening with Fried phenotype or Clinical Frailty Scale[61,62]	Simplify to once-daily LAMA; Assess inhaler technique; consider occupational therapy referral; Caregiver education on device use and symptom monitoring[1,61]
B	mMRC ≥2 **OR** CAT ≥10; 0–1 moderate exacerbations (no hospitalization)	LABA + LAMA dual therapy as preferred initial treatment;[1,59] Pulmonary rehabilitation referral; fewer than 5% of eligible patients receive it[7]	Prioritize LABA + LAMA single-inhaler combination for adherence;[1] Formal pulmonary rehabilitation; 6MWT at baseline; Frail patients show greatest rehabilitation benefit but higher noncompletion risk[62,63]	Focus on symptom relief and functional preservation; Assess cognitive capacity for dual inhaler use; consider once-daily combination device; Home-based rehabilitation if center-based not feasible[61]
E	**≥1 moderate exacerbation OR ≥1 hospitalization in past 12 months (any symptom level)**	LABA + LAMA; consider adding ICS if **eosinophils ≥300 cells/mcL**; Triple therapy reduces exacerbations (RR 0.74 vs. LABA + LAMA) with mortality benefit;[1,64,65] Pulmonary rehabilitation	Triple therapy with ICS pneumonia risk monitoring (OR 1.59 vs. LABA + LAMA; additional 18 pneumonia cases per 1,000 treated);[65] Written action plan with rescue pack; Follow-up every 4–6 wks during escalation[1,62]	Shared decision-making on treatment intensity; document goals of care; Minimize polypharmacy burden; Home-based pulmonary rehabilitation;[61,63] ICS use requires careful risk-benefit assessment given infection susceptibility in frail patients[62,65]

ABBREVIATIONS: *6MWT = 6-Minute Walk Test; CAT = COPD Assessment Test; COPD = Chronic Obstructive Pulmonary Disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease; ICS = Inhaled Corticosteroid; LABA = Long-Acting Beta2-Agonist; LAMA = Long-Acting Muscarinic Antagonist; mMRC = Modified Medical Research Council Dyspnea Scale; OR = Odds Ratio; RR = Rate Ratio*

3 MEAT DOCUMENT ESSENTIALS

Male patient, 71. **Former 40-pack-year smoker** (quit 6 years ago). Established COPD with moderate airflow obstruction (GOLD 2, Group B at last visit). Presents for follow-up after **two urgent care visits in the past 8 months** for worsening dyspnea. Current therapy: tiotropium 18 mcg daily via HandiHaler, albuterol 2 puffs PRN. This encounter requires MEAT documentation to reconfirm HCC 280 status and reassess GOLD group classification given interval exacerbation history.[1]

MONITOR: "COPD follow-up. Dyspnea worse over 3 months; now stops after walking ~1 block. mMRC 3, CAT 22, up from 16 at prior visit. Using albuterol 4–6 times/day. Two moderate exacerbations in past 8 months requiring urgent care and prednisone, no hospitalization. SpO_2 93% RA, down from 95%; weight 154 lb, down 6 lb. Former smoker, no relapse."

EVALUATE: "Spirometry: post-BD FEV_1 1.42 L, 52% predicted; FEV_1/FVC 0.58, consistent with fixed obstruction and GOLD 2 COPD. Prior FEV_1 1.68 L, 61% predicted. CT chest shows moderate bilateral upper-lobe centrilobular emphysema, no acute infiltrate or suspicious nodule. Exam: diminished breath sounds, prolonged expiration, mild expiratory wheeze, no edema or accessory muscle use. Blood eosinophils 340 cells/µL. PHQ-9 = 8."

ASSESS: "COPD with centrilobular emphysema, GOLD 2 with increased symptoms and exacerbation risk; now Group E based on two moderate exacerbations in the past year. Active condition requiring therapy escalation. Eosinophils >300 cells/µL support ICS-containing therapy. Weight loss requires nutrition review and continued malignancy surveillance. Mild depressive symptoms noted."

TREAT: "Stop tiotropium monotherapy. Start triple therapy with fluticasone furoate/umeclidinium/vilanterol 100/62.5/25 mcg, 1 inhalation daily; reviewed inhaler technique and mouth rinsing. Continue albuterol PRN. Written COPD action plan provided: prednisone 40 mg daily × 5 days for future exacerbation symptoms; antibiotics only if increased sputum purulence plus worsening dyspnea, sputum volume, or fever. Pulmonary rehab and nutrition referrals placed. Vaccines reviewed and updated as indicated. Repeat CAT/mMRC and assess inhaler response in 4 weeks; spirometry in 3 months."

Clinical Documentation Elements

Reflecting disease chronicity, severity, and clinical trajectory:

- **Link spirometric data to GOLD severity grade and group classification**: Document FEV1 % predicted, FEV1/FVC ratio, and GOLD grade (1–4) at each encounter. GOLD group (**A/B/E**) classification **drives treatment decisions** and should reflect the most recent 12-month exacerbation history
- **Document emphysema subtype when imaging is available**: CT-identified emphysema (centrilobular, panlobular) should be coded specifically (**J43.1**, **J43.2**) rather than defaulting to unspecified. This supports accurate clinical characterization even when spirometry remains the primary diagnostic tool

- **Record exacerbation history with dates, severity, and treatment**: Each exacerbation event — including urgent care visits, ER visits, and hospitalizations — contributes to GOLD group classification. Document the date, treatment administered, and whether systemic corticosteroids were required
- Specify smoking status with cessation date and pack-year history: Smoking status directly impacts care planning, quality metrics, and prognosis. Former smokers should have quit date documented; current smokers should receive counseling documented at every visit
- Reconfirm COPD as an active, current diagnosis annually: COPD requires annual face-to-face or synchronous audio-video encounter with MEAT documentation by December 31 of each payment year. "History of COPD" language results in Z-code assignment with no HCC mapping

Reframing Common Documentation Shortcuts

INSTEAD OF...	DOCUMENT...	WHY THIS SUPPORTS CLARITY
"COPD, stable"	"COPD, GOLD 2 (FEV1 52% predicted), Group B, on LAMA monotherapy, 0 exacerbations in 12 months, mMRC 1"	Specificity enables accurate GOLD classification, treatment adequacy assessment, and longitudinal tracking
"Emphysema noted on CT"	"Centrilobular emphysema bilateral upper lobes (J43.2) identified on CT [date]; documented as active diagnosis; Spirometry ordered for baseline assessment"	Defines the clinical finding as a codeable diagnosis rather than an incidental observation; **supports HCC 280 mapping**; GOLD 2026 recognizes structural disease independent of airflow obstruction
"Chronic cough, smoker"	"Chronic productive cough ≥3 months (present since [date]) in patient with 35 pack-year smoking history. Meets clinical criteria for chronic bronchitis (J42). Spirometry ordered"	Converts a symptom description into a distinct documented diagnosis with supporting clinical criteria
"Continue inhalers"	"Continue Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) 100/62.5/25 mcg daily (ICS/LAMA/LABA triple therapy). Eosinophils 340, ICS component clinically appropriate per GOLD 2026. Rescue albuterol PRN (current use 2x/day, reduced from 5x/day)"	Documents the clinical reasoning for the current regimen, supporting transparency, continuity, and evidence of appropriate care

INSTEAD OF...	DOCUMENT...	WHY THIS SUPPORTS CLARITY
"COPD exacerbation, treat and release"	"Acute exacerbation of COPD (J44.1), moderate severity per Rome Proposal criteria (VAS 6, SpO2 91%, CRP 14 mg/L); Treated with prednisone 40 mg x 5 days and amoxicillin/clavulanate 875/125 mg BID x 5 days (purulent sputum present); Second exacerbation in 8 months; reclassify to GOLD Group E"	Documents exacerbation severity using Rome Proposal criteria,[4] treatment specifics, antibiotic indication, and the reclassification trigger; Supports PCE quality measure alignment (systemic corticosteroid and/or bronchodilator within required timeframe)
"Sent for PFTs"	"Post-bronchodilator spirometry performed (94060): FEV1/FVC 0.62 (confirms fixed obstruction), FEV1 48% predicted (GOLD 3, severe). Bronchodilator response: +100 mL (3.3% of predicted), below >10% threshold for significant response"	Records specific values that define severity grade, confirm diagnosis, and provide the baseline for longitudinal tracking; Degree of reversibility no longer recommended to guide therapy decisions

ABBREVIATIONS: *BID = Twice Daily; CAT = COPD Assessment Test; COPD = Chronic Obstructive Pulmonary Disease; CRP = C-Reactive Protein; CT = Computed Tomography; FEV1 = Forced Expiratory Volume in 1 Second; FVC = Forced Vital Capacity; GOLD = Global Initiative for Chronic Obstructive Lung Disease; HCC = Hierarchical Condition Category; ICS = Inhaled Corticosteroid; LABA = Long-Acting Beta2-Agonist; LAMA = Long-Acting Muscarinic Antagonist; mMRC = Modified Medical Research Council Dyspnea Scale; PCE = Pharmacotherapy Management of COPD Exacerbation; PFT = Pulmonary Function Test; PRN = As Needed; SpO2 = Oxygen Saturation; VAS = Visual Analog Scale*

4 TREATMENT AND REFERRAL

Therapy Escalation Criteria (GOLD 2026)

TRIGGER	ACTION
Persistent dyspnea on LAMA or LABA monotherapy (mMRC ≥2, CAT ≥10)	Escalate to LABA+LAMA; Confirm inhaler technique and adherence before escalation; DPI devices require adequate inspiratory flow[1]
Exacerbation on bronchodilator monotherapy	Escalate to LABA+LAMA; Document exacerbation date; reassess GOLD group[1]
Moderate or severe exacerbation on LABA+LAMA with eosinophils ≥100 cells/mcL	**Add ICS** to LABA+LAMA (triple therapy); Greater ICS benefit at higher eosinophil counts; Confirm eosinophils within 6 months; Monitor for **ICS-associated pneumonia**[1]

TRIGGER	ACTION
Group E at initial diagnosis with eosinophils ≥300 cells/mcL	Consider LABA+LAMA+ICS as initial therapy (practical recommendation per GOLD 2026). LABA+ICS alone is not encouraged; if ICS indicated, triple therapy is preferred over LABA+ICS[1]
Recurrent exacerbations on triple therapy, eosinophils 100 cells/mcL	Non-smokers: azithromycin 250 mg 3x/week (verify QTc and hearing before initiation; monitor for resistant organisms); FEV1 50% + chronic bronchitis + prior hospitalization: roflumilast 250 mcg x 4 weeks then 500 mcg daily (monitor weight, GI effects)[1]
Recurrent exacerbations on triple therapy, eosinophils ≥300 cells/ mcL	**Specialist referral**; Dupilumab 300 mg SC q^{2} weeks (chronic bronchitis phenotype) or mepolizumab 100 mg SC q^{4} weeks (with or without chronic bronchitis); Document prior therapy failure and eosinophil level at referral[1,70,71]
Severe resting hypoxemia: PaO2 =55 mmHg or SaO2 88%; or PaO2 55 to 60 mmHg with pulmonary HTN, CHF, or hematocrit >55%	Initiate LTOT (≥15 hours/day); Confirm with ABG; reassess at 60 to 90 days; Moderate resting or exercise-induced desaturation alone does not qualify[1,72]
Symptoms persist after bronchodilator and ICS-based options optimized or not tolerated	Last-line: **low-dose theophylline** 200–400 mg/day (target serum 5–10 mcg/mL); Small bronchodilator effect with modest symptomatic benefit; Narrow therapeutic index; interactions with fluoroquinolones, macrolides; Avoid in arrhythmias or hepatic impairment[1]
Confirmed AATD (PiZZ, ZNull, or NullNull genotype) with documented emphysema and FEV1 ≤65% predicted in never- or ex-smoker	Specialist referral for IV augmentation therapy: alpha-1 proteinase inhibitor 60 mg/kg IV weekly;[1,34] ATS recommends augmentation for FEV1 30 to 65% (strong recommendation); for FEV1 <30%, weak recommendation; for FEV1 >65%, individualized discussion;[34] **Not recommended in active smokers**; Code **E88.01** + J43.1 (panlobular emphysema) + J44.x as applicable

ABBREVIATIONS: *LAMA = Long-Acting Muscarinic Antagonist; LABA = Long-Acting Beta2-Agonist; mMRC = Modified Medical Research Council Dyspnea Scale; CAT = COPD Assessment Test; DPI = Dry Powder Inhaler; GOLD = Global Initiative for Chronic Obstructive Lung Disease; ICS = Inhaled Corticosteroid; mcL = Microliter; QTc = Corrected QT Interval; FEV1 = Forced Expiratory Volume in 1 Second; mcg = Microgram; GI = Gastrointestinal; SC = Subcutaneous; PaO2 = Partial Pressure of Oxygen; SaO2 = Arterial Oxygen Saturation; HTN = Hypertension; CHF = Congestive Heart Failure; LTOT = Long-Term Oxygen Therapy; ABG = Arterial Blood Gas; COPD = Chronic Obstructive Pulmonary Disease; AATD = Alpha-1 Antitrypsin Deficiency; PiZZ = Protease Inhibitor ZZ Genotype; IV = Intravenous; ATS = American Thoracic Society*

Evidence-Based Treatment Protocols (GOLD 2026-Aligned)

CATEGORY	RECOMMENDED AGENT/APPROACH	NOTES
Group A: Low symptoms, low risk	**LAMA or LABA monotherapy**; LAMA preferred (RR 0.81 vs. LABA for exacerbation reduction, INVIGORATE trial);[59] Tiotropium 18 mcg daily (HandiHaler) or 2.5 mcg daily (Respimat)	Alternative LABA: salmeterol 50 mcg BID or formoterol 12 mcg BID. Escalate to LABA+LAMA if persistent dyspnea[1]
Group B: High symptoms, low risk	**LABA+LAMA combination** as preferred initial therapy;[1] Umeclidinium/vilanterol (Anoro Ellipta) 62.5/25 mcg daily; or glycopyrrolate/formoterol (Bevespi Aerosphere) 9/4.8 mcg BID	Alternative: tiotropium/olodaterol (Stiolto Respimat) 2.5/2.5 mcg daily; If LABA+LAMA not appropriate, either LAMA or LABA monotherapy; no evidence favoring one class over the other in this scenario[1]
Group E: Exacerbation risk	**LABA+LAMA preferred initial therapy; Add ICS if eosinophils ≥300** (consider triple as initial therapy); Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) 100/62.5/25 mcg daily; or Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) 160/9/4.8 mcg, 2 inhalations BID[67,73]	LABA+LAMA without ICS if eosinophils 100 and no ICS indication; LABA+ICS alone is not encouraged; if ICS needed, use triple therapy[1]
Acute exacerbation: outpatient	Prednisone 40 mg daily x 5 days;[1] albuterol +/- ipratropium via MDI or nebulizer; **If purulent sputum**: amoxicillin/clavulanate 875/125 mg BID x 5 days, or doxycycline 100 mg BID x 5 days, or azithromycin 500 mg day 1 then 250 mg x 4 days[1,7]	Antibiotics shorten recovery and reduce relapse risk in patients with purulent sputum; 5-day corticosteroid course is sufficient for mild to moderate exacerbations[1]
Acute exacerbation: repeated/resistant	**Respiratory fluoroquinolone** (reserve for documented resistance or prior treatment failure); Levofloxacin 750 mg daily x 5 days or moxifloxacin 400 mg daily x 5 days	Culture-directed therapy preferred; Consider azithromycin prophylaxis (250 mg 3x/week) if **≥3 exacerbations/year** in non-smokers[1]
All groups: rescue therapy	Albuterol 90 mcg MDI, 2 puffs q^4 to 6h PRN; or albuterol/ipratropium (Combivent Respimat) 100/20 mcg, 1 inhalation QID PRN	Nebulized albuterol 2.5 mg if MDI technique inadequate; Rescue SABA should be prescribed to all patients for immediate symptom relief[1]

CATEGORY	RECOMMENDED AGENT/APPROACH	NOTES
AATD-associated emphysema (confirmed PiZZ or equivalent)	Standard COPD pharmacotherapy per GOLD group PLUS IV augmentation therapy with alpha-1 proteinase inhibitor (A1-PI) 60 mg/kg weekly;[1,34] FDA-approved products: Prolastin-C (Grifols), Zemaira (CSL Behring), Glassia (Takeda), Aralast NP (Takeda)[74]	Augmentation preserves CT lung density (RAPID trial: 34% reduction in lung density loss vs. placebo at TLC);[75] **Smoking cessation is prerequisite**; cigarette smoke oxidatively inactivates infused AAT;[1,34] **Annual cost ~$100,000+**

ABBREVIATIONS: *LAMA = Long-Acting Muscarinic Antagonist; LABA = Long-Acting Beta2-Agonist; RR = Rate Ratio; mcg = Microgram; BID = Twice Daily; ICS = Inhaled Corticosteroid; MDI = Metered-Dose Inhaler; PRN = As Needed; QID = Four Times Daily; SABA = Short-Acting Beta2-Agonist; AATD = Alpha-1 Antitrypsin Deficiency; PiZZ = Protease Inhibitor ZZ Genotype; COPD = Chronic Obstructive Pulmonary Disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease; IV = Intravenous; A1-PI = Alpha-1 Proteinase Inhibitor; FDA = U.S. Food and Drug Administration; CT = Computed Tomography; TLC = Total Lung Capacity; AAT = Alpha-1 Antitrypsin*

Non-Pharmacologic Treatment and Lifestyle Modification

INTERVENTION	TARGET/RECOMMENDATION	NOTES
Environmental/occupational exposure reduction	Document occupation history and specific exposures; **Refer to occupational medicine if ongoing** dust/fume exposure; Counsel on indoor air quality for biomass fuel users	Occupational exposures account for PAF 14% of COPD (ATS/ERS);[27] 27.3% of US worker COPD cases attributable to work;[28] Exposure reduction impacts disease progression independent of smoking status[1]
Smoking cessation	**Complete cessation**; combination of counseling + pharmacotherapy (varenicline, bupropion, or NRT) achieves long-term quit rates of 14 to 27%;[1] Document pack-years, quit date, and specific intervention at every visit	Single most effective intervention for slowing COPD progression; improves FEV1, reduces exacerbations, and decreases mortality;[1,77] **Approximately 40% of COPD patients continue to smoke despite diagnosis**;[1] Use 5 A's framework (Ask, Advise, Assess, Assist, Arrange)
Pulmonary rehabilitation	**All patients with mMRC ≥2 or CAT ≥10 (Groups B and E);** initiate within 4 weeks of hospitalization for exacerbation (Evidence A/B);[1] Document program, referral date, and functional goal	Post-hospitalization PR reduces readmissions (OR 0.48, 95% CI 0.30 to 0.77);[78] Improves dyspnea, exercise capacity, anxiety/depression, and sleep quality;[1] Fewer than 5% of eligible US patients receive PR;[69] Home-based programs are an alternative if center-based not feasible;[1] Optimal duration: 6 to 8 weeks

INTERVENTION	TARGET/RECOMMENDATION	NOTES
Vaccinations	Influenza (annual); PCV20 or PCV21 (one dose); COVID-19 (per CDC); RSV (age ≥50 or chronic lung disease); Tdap (if not vaccinated in adolescence); zoster (age >50);[1] Document each vaccine with date or document reason for non-receipt	**Influenza vaccination reduces exacerbations, hospitalizations, and death**;[1] Pneumococcal vaccination reduces community-acquired pneumonia and exacerbations (Evidence B);[1] RSV vaccination recommended Evidence A;[1] US adult influenza coverage ~42%; RSV coverage ~17% in adults ≥60[79]
Written action plan + rescue pack	**Personalized written plan** with a pre-prescribed rescue pack (prednisone 40 mg x 5 days +/- antibiotic). Review Green/Yellow/Red zones with patient and caregiver; Update annually and after each exacerbation	Action plans reduce hospital admissions (OR 0.69, 95% CI 0.49 to 0.97; NNT 19) and ED visits (OR 0.55, 95% CI 0.38 to 0.78; NNT 12) over 12 months;[80] Self-management with action plan improves health status and decreases hospitalizations (Evidence B)[1]
Nutritional assessment	Monitor BMI and weight at every visit. Cachexia (BMI =18.5) is an independent predictor of mortality;[1] Document weight trajectory, counseling provided, and dietitian referral when indicated	**Weight loss and muscle wasting carry prognostic importance in severe COPD** but may also signal TB or lung cancer;[1] Skeletal muscle dysfunction is modifiable through rehabilitation and nutritional support[1]
Physical activity	Encourage activity proportionate to functional capacity across all GOLD grades. Physical activity is a strong predictor of mortality (Evidence A);[1] Document activity level and barriers	Behavioral change programs using step counters increase short-term physical activity; [1] Even modest daily walking has measurable benefit at GOLD 1 to 2; Center-based PR complemented with physical activity promotion improves outcomes[1]

ABBREVIATIONS: *5 A's = Ask, Advise, Assess, Assist, Arrange; ATS = American Thoracic Society; BMI = Body Mass Index; CAT = COPD Assessment Test; CDC = Centers for Disease Control and Prevention; CI = Confidence Interval; COPD = Chronic Obstructive Pulmonary Disease; ED = Emergency Department; ERS = European Respiratory Society; FEV1 = Forced Expiratory Volume in 1 Second; GOLD = Global Initiative for Chronic Obstructive Lung Disease; mMRC = Modified Medical Research Council Dyspnea Scale; NNT = Number Needed to Treat; NRT = Nicotine Replacement Therapy; OR = Odds Ratio; PAF = Population Attributable Fraction; PCV20 = 20-Valent Pneumococcal Conjugate Vaccine; PCV21 = 21-Valent Pneumococcal Conjugate Vaccine; PR = Pulmonary Rehabilitation; RSV = Respiratory Syncytial Virus; TB = Tuberculosis; Tdap = Tetanus, Diphtheria, and Pertussis Vaccine*

When to Refer

CRITERION	SPECIALIST	URGENCY
Severe/refractory COPD (GOLD 3 to 4); rapid decline; suspected overlap syndrome; LVRS/transplant evaluation	Pulmonology	Urgent (≤1-2 wks)

CRITERION	SPECIALIST	URGENCY
Diagnostic uncertainty; biologic therapy candidacy; confirmed AATD requiring augmentation therapy	Pulmonology	Prompt (4 to 6 wks)
Suspected cor pulmonale or PH; acute arrhythmia or chest pain during exacerbation; new HF in COPD	Cardiology	Urgent (<1-2 wks)
Elevated BNP in stable COPD; exercise intolerance disproportionate to PFTs; CV risk reassessment	Cardiology	Routine (4–6 wks)
Within 4 weeks of any COPD-related hospitalization or ED visit	Pulmonary Rehabilitation	Prompt (4 wks)
mMRC ≥2 or CAT ≥10; declining exercise tolerance; post-exacerbation recovery	Pulmonary Rehabilitation	Routine (4–6 wks)
Disabling refractory dyspnea at rest; recurrent hospitalizations; estimated life expectancy =6 months	Palliative Care	Urgent (≤1-2 wks)
Persistent symptom burden despite optimized therapy; advance care planning in GOLD 3 to 4	Palliative Care	Routine (4–6 wks)

ABBREVIATIONS: *AATD = Alpha-1 Antitrypsin Deficiency; BNP = B-type Natriuretic Peptide; CAT = COPD Assessment Test; COPD = Chronic Obstructive Pulmonary Disease; CV = Cardiovascular; ED = Emergency Department; GOLD = Global Initiative for Chronic Obstructive Lung Disease; HF = Heart Failure; LVRS = Lung Volume Reduction Surgery; mMRC = Modified Medical Research Council Dyspnea Scale; PFT = Pulmonary Function Test; PH = Pulmonary Hypertension*

Follow-Up Timing

CLINICAL STATUS	TIMING	KEY ASSESSMENT ELEMENT
Post-exacerbation (outpatient)	1–2 wks	Symptom resolution (mMRC, CAT); medication adherence; rescue pack use appropriateness; reassess GOLD group classification (even 1 moderate exacerbation triggers Group E reclassification);[1] Recovery time varies; up to 4–6 wks, with some patients failing to return to pre-exacerbation status[1]
Post-hospitalization for COPD	Early follow-up <4 wks; additional follow-up at 12–16 wks[1]	<4 wks: inhaler technique, supplemental O2 need, symptom scores (CAT/mMRC), comorbidity status, PR eligibility;[1] 12–16 wks: spirometry (FEV1), activities of daily living, LTOT reassessment, comorbidity review;[1] PCE measure: systemic corticosteroid dispensed within 14 days of discharge and bronchodilator within 30 days[81]

CLINICAL STATUS	TIMING	KEY ASSESSMENT ELEMENT
New therapy initiation or escalation	4–6 wks	mMRC, CAT reassessment; inhaler technique and adherence review; side effect screening (ICS: pneumonia risk; LAMA: urinary retention in elderly); If response inadequate, check adherence and comorbidities before further escalation[1]
Stable COPD, Group A/B	Every 3–6 mo	Spirometry at least annually;[1,7] symptom scores (mMRC, CAT); exacerbation count; vaccination status; smoking status; AATD testing if not yet performed[1]
Stable COPD, Group E or GOLD 3–4	Every 2–3 mo	Spirometry every 6–12 mo; eosinophil count if on or considering ICS; weight and BMI monitoring; depression/anxiety screening (PHQ-2, score ≥3 warrants further evaluation);[1] 6MWD; PR engagement; CT if recurrent exacerbations[1]
Annual comprehensive review (all patients)	By Dec 31 (HCC)	MEAT documentation for HCC 280: GOLD spirometric grade + group; all current medications with clinical rationale; exacerbation count (12-mo); smoking status; vaccination status. GOLD 2026 multimorbidity panel: ECG, NT-proBNP, HbA1c, GFR, DXA, PHQ-2/GAD-2, STOP-BANG, 6MWD, SARC-F[1,82]

ABBREVIATIONS: 6MWD = 6-Minute Walk Distance; AATD = Alpha-1 Antitrypsin Deficiency; BMI = Body Mass Index; CAT = COPD Assessment Test; COPD = Chronic Obstructive Pulmonary Disease; CT = Computed Tomography; DXA = Dual-Energy X-ray Absorptiometry; ECG = Electrocardiogram; FEV1 = Forced Expiratory Volume in 1 Second; GAD-2 = Generalized Anxiety Disorder 2-item; GFR = Glomerular Filtration Rate; GOLD = Global Initiative for Chronic Obstructive Lung Disease; HbA1c = Hemoglobin A1c; HCC = Hierarchical Condition Category; ICS = Inhaled Corticosteroid; LAMA = Long-Acting Muscarinic Antagonist; LTOT = Long-Term Oxygen Therapy; MEAT = Monitor, Evaluate, Assess, Treat; mMRC = Modified Medical Research Council Dyspnea Scale; NT-proBNP = N-terminal Pro-B-type Natriuretic Peptide; PCE = Pharmacotherapy Management of COPD Exacerbation; PHQ-2 = Patient Health Questionnaire 2-item; PR = Pulmonary Rehabilitation; SARC-F = Strength, Assistance Walking, Rising From Chair, Climbing Stairs, and Falls; STOP-BANG = Snoring, Tiredness, Observed Apnea, Blood Pressure, BMI, Age, Neck Circumference, Gender

Patient Education and Adherence

COPD management depends on **sustained daily use of inhaled therapies**, avoidance of modifiable risk factors, and prompt self-management of exacerbations. Unlike acute conditions, the benefit of COPD pharmacotherapy is **cumulative** and technique-dependent, making patient understanding of device use, regimen purpose, and action plans critical to outcomes. Non-adherence and inhaler misuse are the **most common correctable causes of treatment failure** before therapy escalation is considered.[1]

Inhaler Technique

- Over two-thirds of patients make at least one critical error in device use; errors are more common with advancing age, cognitive impairment, and reduced manual dexterity
- Use "teach-back" method at every visit: patient demonstrates technique, clinician corrects in real time
- Match device to patient capability: DPI requires adequate inspiratory flow; pMDI with VHC/spacer if coordination is poor; consider nebulizer if neither is feasible

- Prescribe devices with similar inhalation technique when multiple inhalers are needed to reduce confusion

Medication Adherence

- Non-adherence rates range from 22% to 93% across studies, with over half reporting non-adherence in >50% of patients
- Three patterns to identify: erratic (forgetting/busy), unwitting (misunderstanding regimen), and intelligent (deliberate discontinuation because of perceived improvement or side effects)
- Simplify regimens: once-daily dosing and single-inhaler combination devices improve adherence
- Multi-component interventions (education + motivational interviewing + behavioral skills) delivered by pharmacists or nurses are more effective than education alone

Written Action Plan (Exacerbation Self-Management)

- **Personalize with Green/Yellow/Red zones:**
- **Green:** baseline symptoms, continue maintenance therapy
- **Yellow**: increased dyspnea, sputum volume/purulence; initiate rescue pack (prednisone 40 mg x 5 days +/- antibiotic); contact clinic within 48 hours
- **Red**: severe dyspnea at rest, SpO2 <90%, confusion; proceed to ED immediately
- Pre-prescribe rescue pack with clear instructions on when to initiate
- Review and update the plan at least annually and after every exacerbation

Smoking Cessation

- Single most effective intervention for slowing FEV1 decline; address at every encounter
- Document: current status, pack-years, quit date, specific counseling provided, and pharmacotherapy offered (varenicline, bupropion, NRT)

Physical Activity

- Physical activity level is a strong predictor of COPD mortality (Evidence A)
- Encourage daily walking proportionate to functional capacity; step counters and behavioral change programs improve short-term activity levels

DOCUMENTATION: GOOD DOCUMENTATION IS COMPREHENSIVE CODING

Record each education element as a specific clinical action (e.g., "Teach-back inhaler technique performed; 2 critical errors corrected on Ellipta device") rather than generic statements like "patient educated." This supports MEAT documentation and demonstrates active disease management.

Comorbidity Management

COMORBIDITY [RISK]	APPROACH	CAUTION
Heart failure (20 to 30%) [HIGH]	BNP/NT-proBNP screening (NPV 0.80 to 0.98 to exclude LV dysfunction);[1] Echocardiography if abnormal; Selective beta1-blockers (bisoprolol, metoprolol succinate) are safe and recommended in COPD patients with HF;[1,83] Treat HFrEF and HFpEF per cardiology guidelines	Non-selective beta-blockers (propranolol, carvedilol at high doses) **may worsen bronchospasm**;[83] Symptom overlap (dyspnea) complicates diagnosis; **BNP has lower positive predictive value in COPD** than general population;[1] Cardioselective beta-blockers reduce all-cause mortality (HR 0.60, 95% CI 0.48–0.76) and do not impair bronchodilator response[84]
Coronary artery disease (10 to 20%) [HIGH]	CV risk assessment (NHLBI calculator); screen with hs-troponin at COPD diagnosis and at unexplained symptom change (29 to 39% of stable COPD patients have elevated hs-troponin);[1] ECG at baseline. CV event risk elevated during and for ≥1 year post-exacerbation[1]	Cardioselective beta-blockers are remarkably underused in COPD patients with CAD indications; only ~50% receive them despite survival benefit;[83] Treat per cardiology guidelines irrespective of COPD
Atrial fibrillation [MODERATE]	Pulse check at every visit; ECG if irregular rhythm detected;[1] AF more prevalent in COPD-OSA overlap syndrome;[53] Cardioselective beta-blockers are safe in COPD[1,83]	High-dose beta2-agonists and theophylline may worsen AF;[1] Theophylline has narrow therapeutic index with increased arrhythmia risk; avoid in patients on multiple cardiac medications[1]
Type 2 diabetes (~20%) [MODERATE]	HbA1c and fasting glucose if not tested within 1 year;[1] Monitor glucose during systemic corticosteroid courses: hyperglycemia risk increased 2.4-fold (RR 2.39, 95% CI 1.51 to 3.78) with systemic glucocorticoids;[85] Prednisone 40 mg x 5 days is still indicated for exacerbations; adjust DM medications temporarily[1]	High-dose ICS associated with worsening DM control;[1] Systemic corticosteroids during exacerbations cause hyperglycemia in ~39% of treated patients, enhancing infection risk;[1,85] Use systemic corticosteroids at lowest dose for shortest time[1]

COMORBIDITY [RISK]	APPROACH	CAUTION
Depression/ Anxiety [HIGH]	PHQ-2 for depression (score ≥3 warrants further evaluation); GAD-2 for anxiety (same threshold);[1] SSRIs preferred for depression; buspirone for anxiety; Pulmonary rehabilitation combined with CBT effective for both[1]	Benzodiazepines increase risk of COPD hospitalization (aOR 1.42, 95% CI 1.21 to 1.66 for benzodiazepine alone; aOR 2.32 for concurrent opioid/benzodiazepine use);[86] Respiratory depression risk; impaired cough reflex; sedation worsens hypercapnia; Avoid long-term use[87]
Osteoporosis (up to 30% women, 18% men) [MODERATE]	DEXA scan if ICS use, systemic steroid history, or low BMI; Chest CT can help identify low BMD;[1] Calcium + vitamin D supplementation[1]	ICS increases pneumonia risk (OR 1.38, 95% CI 1.02–1.88 vs. placebo; dose-dependent);[88] Prolonged or repeated systemic corticosteroid courses accelerate bone loss; limit prednisone bursts to 5 days;[1] Avoid repeated systemic courses when possible
OSA/Overlap syndrome (~28% globally) [MODERATE]	STOP-BANG questionnaire if obesity, snoring, daytime somnolence, or hypertension;[1] Polysomnography if clinical suspicion. CPAP reduces all-cause hospitalizations, ER visits, exacerbations, and mortality in overlap syndrome[1]	Overlap patients have worse prognosis than either condition alone: more profound nocturnal desaturation, higher pulmonary hypertension risk, and more cardiac arrhythmias;[1] Undertreating either condition independently worsens outcomes[1]
GERD (17 to 78%) [LOW]	Symptom assessment; empiric PPI trial may improve symptoms and decrease exacerbation risk;[1] Weight loss if obese; avoid late-night meals; semi-recumbent sleeping posture[1]	GERD is an independent risk factor for COPD exacerbations (OR 5.37, 95% CI 2.71 to 10.64);[89] COPD medications (theophylline, beta2-agonists, anticholinergics) may alter esophageal sphincter tone and worsen GERD;[90] Surgical fundoplication if conservative therapy fails[1]

ABBREVIATIONS: *AF = Atrial Fibrillation; aOR = Adjusted Odds Ratio; BNP = B-type Natriuretic Peptide; BMD = Bone Mineral Density; BMI = Body Mass Index; CAD = Coronary Artery Disease; CBT = Cognitive Behavioral Therapy; CI = Confidence Interval; COPD = Chronic Obstructive Pulmonary Disease; CPAP = Continuous Positive Airway Pressure; CT = Computed Tomography; CV = Cardiovascular; DEXA = Dual-Energy X-ray Absorptiometry; DM = Diabetes Mellitus; ECG = Electrocardiogram; ER = Emergency Room; GAD-2 = Generalized Anxiety Disorder 2-item; GERD = Gastroesophageal Reflux Disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease; HbA1c = Hemoglobin A1c; HF = Heart Failure; HFpEF = Heart Failure with Preserved Ejection Fraction; HFrEF = Heart Failure with Reduced Ejection Fraction; HR = Hazard Ratio; hs-troponin = High-Sensitivity Troponin; ICS = Inhaled Corticosteroid; LV = Left Ventricular; NHLBI = National Heart, Lung, and Blood Institute; NPV = Negative Predictive Value; NT-proBNP = N-terminal Pro-B-type Natriuretic Peptide; OR = Odds Ratio; OSA = Obstructive Sleep Apnea; PHQ-2 = Patient Health Questionnaire 2-item; PPI = Proton Pump Inhibitor; RR = Risk Ratio; SSRI = Selective Serotonin Reuptake Inhibitor; T2DM = Type 2 Diabetes Mellitus*

Cost-Smart Options

BRAND (EST. COST)	GENERIC/ ALTERNATIVE (EST. COST)	EST. MONTHLY SAVINGS	COST-SMART TIP
Trelegy Ellipta (ICS+LAMA+LABA triple therapy; ~$420/mo[91]	Breztri Aerosphere (**~$410/mo**)	N/A	**No generic triple inhaler available**;[92] Similar price between both on-brand triple inhalers
Anoro Ellipta (LAMA+LABA) ~$290/mo)	Generic umeclidinium/ vilanterol (**~$275/mo**); Stiolto Respimat (tiotropium/ olodaterol) ~$630/ mo	~$15/mo with generic option	Authorized generic available (Prasco); once-daily LAMA+LABA **preferred initial therapy for Group B and Group E**. Annualized total COPD costs $10,094 with LAMA+LABA vs. $17,135 with triple therapy in matched Medicare cohorts
Spiriva HandiHaler/ Respimat (tiotropium brand; ~$590/mo)	Generic tiotropium DPI (**~$370/mo** where available); Incruse Ellipta (umeclidinium) **~$430/mo**	~$160-$220/ mo	**First-line LAMA for Group A**; generic tiotropium DPI availability makes this the most cost-effective maintenance option; LAMA preferred over LABA for greater exacerbation reduction (RR 0.81)
Albuterol brand MDI (ProAir/Ventolin; ~$30 to 70/mo)	Generic albuterol HFA MDI (~$10 to 25/mo)	~$20-$45/mo	Universal rescue inhaler for all COPD patients; **Multiple FDA-approved generics available**

ABBREVIATIONS: *ICS = Inhaled Corticosteroid; LAMA = Long-Acting Muscarinic Antagonist; LABA = Long-Acting Beta2-Agonist; COPD = Chronic Obstructive Pulmonary Disease; DPI = Dry Powder Inhaler; MDI = Metered-Dose Inhaler; GOLD = Global Initiative for Chronic Obstructive Lung Disease; RR = Rate Ratio; HFA = Hydrofluoroalkane; FDA = US Food and Drug Administration*

COPD Quality Metric Tie-Ins

2026 MEASURE	STANDARD	NOTES
NCQA HEDIS PCE-C: Systemic Corticosteroid Component	Systemic corticosteroid **dispensed within 14 days** of discharge for COPD exacerbation (J44.1); Ages ≥40 with COPD-related inpatient or ED visit	Both PCE-C and PCE-D must be met for full measure compliance; **Document discharge diagnosis clearly as J44.1 to trigger measure**; ensure prescriptions are transmitted before or at discharge to avoid compliance gaps

2026 MEASURE	STANDARD	NOTES
NCQA HEDIS PCE-D: Bronchodilator Component	Bronchodilator **dispensed within 30 days** of discharge for COPD exacerbation; Ages ≥40 with COPD-related inpatient or ED visit	Both PCE-C and PCE-D must be met for full measure compliance; **Document discharge diagnosis clearly as J44.1 to trigger measure**; ensure prescriptions are transmitted before or at discharge to avoid compliance gaps
MIPS #052: COPD: Long-Acting Inhaled Bronchodilator Therapy	**Denominator**: Patients aged ≥18 with COPD (J44.x) and FEV1/FVC <0.70 documented during the performance period; **Numerator**: Patients prescribed or actively using a long-acting inhaled bronchodilator (LAMA, LABA, or LAMA+LABA combination)	Process measure; aligns with GOLD 2026 Evidence A recommendation that LABAs and LAMAs are preferred over short-acting agents for all patients except those with only occasional dyspnea; LAMA preferred over LABA for greater exacerbation reduction (RR 0.81, INVIGORATE); **Confirm spirometric documentation of obstruction** (post-BD FEV1/FVC <0.70) to satisfy denominator criteria; report via claims, registry, or EHR; **Exclusions**: Patients with documented contraindication or medical reason for not prescribing

ABBREVIATIONS: *NCQA = National Committee for Quality Assurance; HEDIS = Healthcare Effectiveness Data and Information Set; PCE = Pharmacotherapy Management of COPD Exacerbation; COPD = Chronic Obstructive Pulmonary Disease; ED = Emergency Department; MIPS = Merit-based Incentive Payment System; FEV1 = Forced Expiratory Volume in 1 Second; FVC = Forced Vital Capacity; LAMA = Long-Acting Muscarinic Antagonist; LABA = Long-Acting Beta2-Agonist; GOLD = Global Initiative for Chronic Obstructive Lung Disease; RR = Rate Ratio; BD = Bronchodilator; EHR = Electronic Health Record*

5 CODING REMINDERS AND CASE EXAMPLES

Coding Specificity

CRITICAL ELEMENT	CLINICAL REQUIREMENT	EXAMPLE DOCUMENTATION
Active vs. history framing	Document COPD as active, current condition; "History of" generates Z-codes without HCC 280 mapping	"Active COPD, GOLD 2 (FEV1 55%), Group B, on LAMA+LABA; MEAT reconfirmed today."
Emphysema subtype specificity	Document specific subtype on CT (J43.1 panlobular, J43.2 centrilobular); do not default to J43.9. Document even if PFTs are normal	"Centrilobular emphysema bilateral upper lobes on CT [date] (J43.2). Spirometry ordered. Active diagnosis, pre-COPD state per GOLD 2026."

CRITICAL ELEMENT	CLINICAL REQUIREMENT	EXAMPLE DOCUMENTATION
Chronic bronchitis clinical criteria	Productive cough ≥3 mo in 2 consecutive yrs = chronic bronchitis (J42/J41.x). Code independent of spirometry	"Daily productive cough since [date], >3 months. Chronic bronchitis (J42) with a 30-pack-year history. Spirometry ordered."
Exacerbation vs. infection distinction	**J44.1** (exacerbation) and **J44.0** (COPD with infection) are distinct; **J44.0** requires additional code for the **specific organism**	"J44.1: Acute exacerbation, moderate severity." OR "J44.0: COPD with LRTI due to S. pneumoniae (B95.3)."
GOLD group classification documentation	Document group (A/B/E) annually using mMRC/CAT and 12-month exacerbation history. Group assignment drives therapy	"Reclassified to Group E: 2 moderate exacerbations in 12 months. mMRC 3, CAT 22. Triple therapy initiated."
Spirometric severity	Record FEV1 % predicted and GOLD grade (1 to 4) for severity characterization and longitudinal tracking	"Post-BD spirometry: FEV1/FVC 0.58, FEV1 48% predicted, GOLD 3 (severe). Declined from 61% [date]."
Eosinophil for ICS decisions	Document blood eosinophil count with ICS rationale. Thresholds: ≥300 to initiate ICS; ≥100 with breakthrough exacerbation to add ICS	"Eosinophils 340 cells/mcL [date]. ICS added per GOLD 2026: eosinophils ≥300 supports ICS benefit."
Respiratory failure coding (secondary)	**J96.x** sequenced secondary to COPD; Specify type (hypoxemic/ hypercapnic) and acuity (acute, chronic, acute-on-chronic)	"J44.1 with acute-on-chronic hypercapnic respiratory failure (J96.22). PaCO2 58 mmHg, pH 7.32."

ABBREVIATIONS: *BD = Bronchodilator; CAT = COPD Assessment Test; COPD = Chronic Obstructive Pulmonary Disease; CT = Computed Tomography; FEV1 = Forced Expiratory Volume in 1 Second; FVC = Forced Vital Capacity; GOLD = Global Initiative for Chronic Obstructive Lung Disease; HCC = Hierarchical Condition Category; ICS = Inhaled Corticosteroid; LABA = Long-Acting Beta2-Agonist; LAMA = Long-Acting Muscarinic Antagonist; LRTI = Lower Respiratory Tract Infection; MEAT = Monitor, Evaluate, Assess, Treat; mMRC = Modified Medical Research Council Dyspnea Scale; PaCO2 = Partial Pressure of Carbon Dioxide; PFT = Pulmonary Function Test*

Annual Clinical Review and Confirmation

- **Annual review requirement:** COPD must be reassessed at least once per calendar year via face-to-face or synchronous audio-video encounter, with all four MEAT elements documented by December 31 of the payment year. The clinical encounter must demonstrate that the provider reviewed the condition, assessed its current status, and made or confirmed a management plan
- **HCC context:** All COPD-spectrum diagnoses (J44.x, J43.x, J41.x, J42) map to HCC 280 (RAF 0.319). If COPD is documented as "history of" or placed on a historical problem list without

annual clinical reconfirmation, it will **not map to HCC 280 for the current payment year;** the clinical complexity represented by the COPD diagnosis will be absent from the patient's risk profile

- **Reconfirm GOLD classification annually:** GOLD spirometric grade (1–4 based on FEV1 % predicted) and GOLD group (A/B/E based on symptoms and exacerbation history) should be **reassessed at each annual review**. Disease progression may change both grade and group classification, directly affecting treatment recommendations
- **Update spirometric data:** Annual spirometry (or at minimum a clinician statement referencing the most recent spirometric values and date) is recommended for established COPD. Document FEV1 % predicted, FEV1/FVC ratio, and trajectory compared to prior measurements. Annual FEV1 decline >40 mL/year suggests accelerated progression warranting treatment reassessment
- **Document exacerbation history:** Count all moderate and severe exacerbations in the prior 12 months. This directly determines GOLD group classification (Group E = ≥1 moderate exacerbation requiring systemic corticosteroids, or any hospitalization). Include dates and treatment provided for each event
- **Review and update all active medications:** Document every current COPD medication with dose, frequency, and route. Note inhaler technique assessment. Document the clinical rationale for the current regimen, particularly ICS use relative to blood eosinophil count
- **Confirm AATD screening has been performed**: All COPD patients should have **at least one documented serum AAT level** (CPT 82103); if below 1.1–1.3g/L, **genotyping** (*SERPINA1*) is indicated. If confirmed (PiZZ/PiSZ/null), add **E88.01** alongside J43.x/J44.x and refer to a specialist center for **augmentation therapy evaluation**

Good Documentation is Comprehensive Coding

INSUFFICIENT	COMPREHENSIVE
"COPD, stable, continue meds."	"COPD, GOLD 2, Group B; FEV_1 55% predicted, mMRC 1, CAT 12, 0 exacerbations in 12 mo. Symptoms controlled on tiotropium daily. Active dx reconfirmed; spirometry due [date]."
"Emphysema on CT, follow up."	"Centrilobular emphysema on CT [date], bilateral upper lobes (J43.2). Former smoker, 35 pack-years, quit [date]. Spirometry ordered to assess airflow obstruction; smoking abstinence reinforced."
"Chronic cough — smoker. Continue albuterol PRN."	"Chronic productive cough ≥3 mo in active smoker, 40 pack-years. Spirometry: FEV_1/FVC 0.64, FEV_1 68% predicted, GOLD 2 COPD/chronic bronchitis. Started tiotropium; smoking cessation counseling + NRT prescribed."

INSUFFICIENT	COMPREHENSIVE
"COPD exacerbation. Prednisone and Z-pack."	"AECOPD (J44.1), moderate: worsening dyspnea, SpO_2 91% from baseline 95%, ↑ sputum purulence. Treated with prednisone ×5 d + azithromycin. Second moderate exacerbation in 8 mo; reassess GOLD group and controller therapy."
"COPD, refill inhalers. History of smoking."	"Active COPD with centrilobular emphysema, GOLD 3, Group E; FEV_1 42% predicted, 3 exacerbations in 12 mo. On triple therapy; albuterol use improved to 1–2×/wk. mMRC 2, CAT 18. Pulm rehab ongoing. Former smoker, 45 pack-years, quit [date]. MEAT documented."

ABBREVIATIONS: *AECOPD = acute exacerbation of COPD; CAT = COPD Assessment Test; COPD = chronic obstructive pulmonary disease; CT = computed tomography; dx = diagnosis; FEV_1 = forced expiratory volume in 1 second; FVC = forced vital capacity; GOLD = Global Initiative for Chronic Obstructive Lung Disease; MEAT = Monitor, Evaluate, Assess, Treat; mMRC = modified Medical Research Council dyspnea scale; NRT = nicotine replacement therapy; PRN = as needed; pulm rehab = pulmonary rehabilitation; SpO_2 = oxygen saturation.*

EHR Workflow Tips

- **Use one COPD MEAT smart phrase:** Pull mMRC/CAT, SpO_2, rescue inhaler use, exacerbations in past 12 months, spirometry with date, eosinophils, smoking status, current inhalers, and follow-up plan
- **Keep GOLD classification visible:** Document GOLD grade from spirometry and GOLD group A/B/E from symptoms and exacerbation history; update when symptoms or exacerbation pattern changes
- **Use a spirometry/exacerbation review prompt:** Flag active J44.x/J43.x/J41.x/J42 when spirometry is outdated or exacerbation history is missing. Use a non-interruptive prompt rather than a hard-stop alert
- **Build a focused COPD order set:** Include spirometry, CBC with differential/eosinophils, vaccination review, smoking cessation support, and PHQ-9 when clinically relevant. Add BNP, DEXA, or BMP only when symptoms, steroid exposure, or treatment risks justify it
- **Prompt pulmonary rehab and action planning:** After COPD-related ED visit, hospitalization, or recurrent exacerbations, prompt referral to pulmonary rehabilitation and document the COPD action plan, inhaler technique, rescue medication plan, and follow-up timing

Brief Case Examples

✓ SUCCESS — COMPLETE DISEASE STATUS DOCUMENTATION

SCENARIO: **68-year-old female**. Former 35-pack-year smoker, quit 4 years ago. CT chest ([date]): centrilobular emphysema bilateral upper lobes. Post-bronchodilator spirometry: FEV1/FVC 0.62, FEV1 56% predicted (GOLD 2, moderate). mMRC 2, CAT 18. One moderate exacerbation in past 12

months (treated with prednisone burst [date]). Classified GOLD Group E (≥1 moderate exacerbation per GOLD 2026). Blood eosinophils 310 cells/mcL. Initiated triple therapy: fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) 100/62.5/25 mcg daily (ICS appropriate given eosinophils ≥300 per GOLD 2026). Rescue pack prescribed (prednisone 40 mg x 5 days + amoxicillin/clavulanate 875/125 mg BID x 5 days) with written action plan. Pulmonary rehabilitation referral placed. Influenza vaccine administered today; PCV20 and RSV vaccine documented as current.

→ **HCC 280** (RAF 0.319). MEAT criteria fully met: spirometric severity documented (GOLD 2), Group E classification with exacerbation date, treatment escalation grounded in eosinophil count (310 cells/mcL), comorbidity-aware prescribing, and preventive care completed. Rescue pack and written action plan support early self-management.

⚠ PITFALL — STATIC LABEL WITH MISSING SPECIFICITY

SCENARIO: **74-year-old male**. "COPD, stable. Continue inhalers. History of smoking." Problem list includes "COPD" **without ICD-10 specificity**. On tiotropium and albuterol PRN for 3 years. No spirometry on file since 2022. No mMRC or CAT documented. Two urgent care visits for "bronchitis" in the past year were treated with antibiotics but not coded as COPD exacerbations. No eosinophil count. CT 18 months ago showed emphysema but was not documented as a coded diagnosis. No rescue pack or action plan.

→ Problems: Emphysema subtype **undocumented** (J43.9 default vs. specific subtype). GOLD group indeterminate from the record; patient appears undertreated for actual disease burden (likely Group E based on exacerbation history). PCE measure opportunity missed at both exacerbation episodes (systemic corticosteroid within 14 days and bronchodilator within 30 days of discharge not documented). No AATD screening documented. The care plan cannot be accurately assessed, continued, or handed off based on this documentation.

✓ FIX — CORRECTED DOCUMENTATION

SCENARIO

74-year-old male. Former 45-pack-year smoker, quit [date]. CT [date]: centrilobular emphysema bilateral upper lobes, documented as J43.2 (centrilobular emphysema), active diagnosis. Post-bronchodilator spirometry performed today (94060): FEV1/FVC 0.56, FEV1 44% predicted (GOLD 3, severe). Two moderate exacerbations in past 12 months ([date], [date]), both confirmed as COPD exacerbations (J44.1) retrospectively after chart review of urgent care notes. Reclassified to GOLD Group E (≥1 moderate exacerbation per GOLD 2026). mMRC 3, CAT 24. Blood eosinophils 220 cells/mcL ([date]). Escalated from LAMA monotherapy to LABA+LAMA dual therapy: umeclidinium/vilanterol (Anoro Ellipta) 62.5/25 mcg daily. Eosinophils 220 cells/mcL (above 100 threshold with recurrent exacerbations; ICS addition reasonable per GOLD 2026 but deferred pending reassessment at next exacerbation or follow-up eosinophil count). Rescue pack prescribed with a written action plan. Pulmonary rehabilitation referral placed. PHQ-9: 12 (moderate depression), SSRI discussion initiated. DEXA ordered (repeated systemic corticosteroid exposure from exacerbation bursts). AATD screening ordered (82103, serum AAT level; not previously performed). Follow-up 4 weeks.

→ **HCC 280** (RAF 0.319). The clinical record now captures: emphysema subtype from imaging (J43.2), spirometric severity (GOLD 3), prior exacerbation history with Group E reclassification, evidence-based treatment escalation with documented ICS decision rationale, depression screening (PHQ-9: 12), osteoporosis assessment ordered, AATD screening initiated, and rescue pack with written action plan in place.

REFERENCES

1.Global Initiative for Chronic Obstructive Lung Disease (GOLD). *Global Strategy for Prevention, Diagnosis, and Management of COPD: 2026 Report*. Global Initiative for Chronic Obstructive Lung Disease; 2025. https://goldcopd.org/wp-content/uploads/2026/01/GOLD-REPORT-2026-v1.3-8Dec2025_WMV2.pdf*

2.Adeloye D, Song P, Zhu Y. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. *Lancet Respir Med*. 2022;10(5):447-458. doi:10.1016/S2213-2600(21)00511-7

3.Centers for Medicare & Medicaid Services. *2026 Final ICD-10-CM Mappings (CMS-HCC V28)*. U.S. Department of Health and Human Services; 2025. https://www.cms.gov/medicare/health-plans/medicareadvtgspecratestats/risk-adjustors/2026-model-software

4.Celli B, Fabbri L, Aaron S, et al. Definition and nomenclature of chronic obstructive pulmonary disease exacerbations: a proposal from the Rome meeting. *Am J Respir Crit Care Med*. 2021;204(11):1251-1258. doi:10.1164/rccm.202108-1819PP

5.Centers for Medicare & Medicaid Services. *CMS-HCC Model Relative Factor Tables (Community, Non-Dual, Aged)*. 2024. https://www.cms.gov/files/document/revised-cms-hcc-model-relative-factor-tablespdf

6.Bhatt S, Abadi E, Engel K. A Multidimensional Diagnostic Approach for Chronic Obstructive Pulmonary Disease. *JAMA*. 2025;333(24):2164-2175. doi:10.1001/jama.2025.7358

7.Riley C, Sciurba F. Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review. *JAMA*. 2019;321(8):786-797. doi:10.1001/jama.2019.0131

8.Weeks J, Elgaddal N. Chronic Obstructive Pulmonary Disease in Adults Age 18 and Older: United States, 2023. *NCHS Data Brief*. 2025;(529):. doi:10.15620/cdc/174596

9.Liu Y, Carlson S, Watson K, Xu F, Greenlund K. Trends in the Prevalence of Chronic Obstructive Pulmonary Disease Among Adults Aged >=18 Years -- United States, 2011-2021. *MMWR Morb Mortal Wkly Rep*. 2023;72(46):1250-1256. doi:10.15585/mmwr.mm7246a

10.Tejada-Vera B, Bastian B, Curtin S. Deaths: Leading Causes for 2023. *Natl Vital Stat Rep*. 2025;(10):. doi:10.15620/cdc/174607

11.Rojas J, Chokkara S, Zhu M, Lindenauer P, Press V. Care Quality for Patients With Chronic Obstructive Pulmonary Disease in the Readmission Penalty Era. *Am J Respir Crit Care Med*. 2023;207(1):. doi:10.1164/rccm.202203-0496OC

12.Puebla Neira D, Hsu E, Kuo Y, Ottenbacher K, Sharma G. Readmissions Reduction Program: Mortality and Readmissions for Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med*. 2021;203(4):437-446. doi:10.1164/rccm.202002-0310OC

13.Lindenauer P, Dharmarajan K, Qin L, Lin Z, Gershon A, Krumholz H. Risk Trajectories of Readmission and Death in the First Year After Hospitalization for Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med*. 2018;197(8):1009-1017. doi:10.1164/rccm.201709-1852OC

14.Mannino D, Roberts M, Mapel D, et al. National and Local Direct Medical Cost Burden of COPD in the United States From 2016 to 2019 and Projections Through 2029. *Chest*. 2024;165(5):1093-1106. doi: 10.1016/j.chest.2023.11.040

15.Sethi S, Make B, Robinson S, et al. Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-for-Service Population. *Int J Chron Obstruct Pulmon Dis*. 2022;:593-608. doi:10.2147/COPD.S350248

16.Graham B, Steenbruggen I, Miller M, et al. Standardization of Spirometry 2019 Update: An Official American Thoracic Society and European Respiratory Society Technical Statement. *Am J Respir Crit Care Med*. 2019;200(8):e70-e. doi:10.1164/rccm.201908-1590ST

17.Singh D, Stockley R, Anzueto A, et al. GOLD Science Committee Recommendations for the Use of Pre- and Post-Bronchodilator Spirometry for the Diagnosis of COPD. *Eur Respir J*. 2025;65(2):2401603. doi: 10.1183/13993003.01603-2024

18.Celli B, Wedzicha J. Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. *N Engl J Med*. 2019;381(13):1257-1266. doi:10.1056/NEJMra1900500

19.Balasubramanian A, MacIntyre N, Henderson R, et al. Diffusing Capacity of Carbon Monoxide in Assessment of COPD. *Chest*. 2019;156(6):1111-1119. doi:10.1016/j.chest.2019.06.035

20.US Preventive Services Task Force, Mangione C, Barry M, et al. Screening for Chronic Obstructive Pulmonary Disease: US Preventive Services Task Force Reaffirmation Recommendation Statement. *JAMA*. 2022;327(18):1806-1811. doi:10.1001/jama.2022.5692

21.Strnad P, McElvaney N, Lomas D. Alpha1-Antitrypsin Deficiency. *N Engl J Med*. 2020;382(15): 1443-1455. doi:10.1056/NEJMra1910234

22.Hernandez P, Bossé Y, Bush P, et al. Alpha-1-Antitrypsin Deficiency Targeted Testing and Augmentation Therapy: A Canadian Thoracic Society Meta-Analysis and Clinical Practice Guideline. *Chest*. 2025;167(4):1044-1063. doi:10.1016/j.chest.2024.08.037

23.Oh A, Strand M, Pratte K, et al. Visual Emphysema at Chest CT in GOLD Stage 0 Cigarette Smokers Predicts Disease Progression: Results From the COPDGene Study. *Radiology*. 2020;296(3):641-649. doi:10.1148/radiol.2020192429

24.Oshaug K, Halvorsen P, Melbye H. Should Chest Examination Be Reinstated in the Early Diagnosis of Chronic Obstructive Pulmonary Disease? *Int J Chron Obstruct Pulmon Dis*. 2013;:369-377. doi: 10.2147/COPD.S47992

25.Wheaton A, Liu Y, Croft J, et al. Chronic Obstructive Pulmonary Disease and Smoking Status - United States, 2017. *MMWR Morb Mortal Wkly Rep*. 2019;68(24):533-538. doi:10.15585/mmwr.mm6824a

26.Hnizdo E, Sullivan P, Bang K, Wagner G. Association Between Chronic Obstructive Pulmonary Disease and Employment by Industry and Occupation in the US Population: A Study of Data From the Third National Health and Nutrition Examination Survey. *Am J Epidemiol*. 2002;156(8):738-746. doi: 10.1093/aje/kwf

27.Blanc P, Annesi-Maesano I, Balmes J, et al. The Occupational Burden of Nonmalignant Respiratory Diseases: An Official American Thoracic Society and European Respiratory Society Statement. *Am J Respir Crit Care Med*. 2019;199(11):1312-1334. doi:10.1164/rccm.201904-0717ST

28.Syamlal G, Doney B, Hendricks S, Mazurek J. Chronic Obstructive Pulmonary Disease and U.S. Workers: Prevalence, Trends, and Attributable Cases Associated With Work. *Am J Prev Med*. 2021;61(3):e127-e. doi:10.1016/j.amepre.2021.04.011

29.Duan P, Wang Y, Lin R, et al. Impact of Early Life Exposures on COPD in Adulthood: A Systematic Review and Meta-Analysis. *Respirology*. 2021;26(12):1131-1151. doi:10.1111/resp.14144

30.Feng J, Hu M, Duan H. Bidirectional Association Between Tuberculosis and Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. *J Clin Med*. 2025;14(21):7639. doi: 10.3390/jcm14217639

31.Sandhaus R, Strange C, Stone G, Guo J, Engel-Nitz N, Goss T. Comorbidity Associations With AATD Among Commercially Insured and Medicare Beneficiaries With COPD in the US. *Int J Chron Obstruct Pulmon Dis*. 2020;:2389-2397. doi:10.2147/COPD.S263297

32.Molloy K, Hersh C, Morris V, et al. Clarification of the Risk of Chronic Obstructive Pulmonary Disease in Alpha1-Antitrypsin Deficiency PiMZ Heterozygotes. *Am J Respir Crit Care Med*. 2014;189(4):419-427. doi:10.1164/rccm.201311-1984OC

33.Canepa M, Franssen F, Olschewski H. Diagnostic and Therapeutic Gaps in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease. *JACC Heart Fail*. 2019;7(10):823-833. doi:10.1016/j.jchf.2019.05.009

34.Sandhaus R, Turino G, Brantly M. The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. *Chronic Obstr Pulm Dis*. 2016;3(3):668-682. doi:10.15326/jcopdf.3.3.2015.0182

35.Riley L, Sriram A, Brantly M, Lascano J. Testing Patterns and Disparities for Alpha-1 Antitrypsin Deficiency. *Am J Med*. 2023;136(10):1011-1017. doi:10.1016/j.amjmed.2023.06.020

36.Stoller J. Detecting Alpha-1 Antitrypsin Deficiency: Current State, Impediments, Opportunities, and Future Directions. *Ann Am Thorac Soc*. Published online September 23, 2024. doi:10.1513/AnnalsATS.202406-600FR

37.Leung C, Sin D. Asthma-COPD Overlap: What Are the Important Questions? *Chest*. 2022;161(2):330-344. doi:10.1016/j.chest.2021.09.036

38.Heidenreich P, Bozkurt B, Aguilar D. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. *J Am Coll Cardiol*. 2022;79(17):e263-e421. doi:10.1016/j.jacc.2021.12.012

39.McCracken J, Veeranki S, Ameredes B, Calhoun W. Diagnosis and Management of Asthma in Adults: A Review. *JAMA*. 2017;318(3):279-290. doi:10.1001/jama.2017.8372

40.Lynch D, Austin J, Hogg J. CT-Definable Subtypes of Chronic Obstructive Pulmonary Disease: A Statement of the Fleischner Society. *Radiology*. 2015;277(1):192-205. doi:10.1148/radiol.2015141579

41.Barker A, Karamooz E. Non-Cystic Fibrosis Bronchiectasis in Adults: A Review. *JAMA*. 2025;334(3):253-264. doi:10.1001/jama.2025.2680

42.Rizkallah J, Man S, Sin D. Prevalence of Pulmonary Embolism in Acute Exacerbations of COPD: A Systematic Review and Metaanalysis. *Chest*. 2009;135(3):786-793. doi:10.1378/chest.08-1516

43.Couturaud F, Bertoletti L, Pastre J. Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms. *JAMA*. 2021;325(1):. doi:10.1001/jama.2020.23567

44.Celli B, Fabbri L, Aaron S. Differential Diagnosis of Suspected Chronic Obstructive Pulmonary Disease Exacerbations in the Acute Care Setting: Best Practice. *Am J Respir Crit Care Med*. 2023;207(9):1134-1144. doi:10.1164/rccm.202209-1795CI

45.Singh D, Agusti A, Martinez F. Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. *Am J Respir Crit Care Med*. 2022;206(1):. doi:10.1164/rccm.202201-0209PP

46.Roversi S, Fabbri L, Sin D, Hawkins N, Agusti A. Chronic Obstructive Pulmonary Disease and Cardiac Diseases: An Urgent Need for Integrated Care. *Am J Respir Crit Care Med*. 2016;194(11):1319-1336. doi:10.1164/rccm.201604-0690SO

47.Carter P, Lagan J, Fortune C. Association of Cardiovascular Disease With Respiratory Disease. *J Am Coll Cardiol*. 2019;73(17):2166-2177. doi:10.1016/j.jacc.2018.11.063

48.Javaheri S, Javaheri S, Somers V. Interactions of Obstructive Sleep Apnea With the Pathophysiology of Cardiovascular Disease, Part 1: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2024;84(13): 1208-1223. doi:10.1016/j.jacc.2024.02.059

49.Anghel L, Ciubara A, Patras D, Ciubara A. Chronic Obstructive Pulmonary Disease and Type 2 Diabetes Mellitus: Complex Interactions and Clinical Implications. *J Clin Med*. 2025;14(6):1809. doi:10.3390/jcm14061809

50.Xie H, Jiang Y, Liu L. Global Prevalence and Risk Factors of Depression in Patients With Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis From 2000 to 2022. *J Psychosom Res*. 2023;:111537. doi:10.1016/j.jpsychores.2023.111537

51.Pollok J, van Agteren J, Carson-Chahhoud K. Pharmacological Interventions for the Treatment of Depression in Chronic Obstructive Pulmonary Disease. *Cochrane Database Syst Rev*. 2018; (12):CD012346. doi:10.1002/14651858.CD012346.pub

52.Janson C, Lisspers K, Stallberg B. Osteoporosis and Fracture Risk Associated With Inhaled Corticosteroid Use Among Swedish COPD Patients: The ARCTIC Study. *Eur Respir J*. 2021;57(2): 2000515. doi:10.1183/13993003.00515-2020

53.Li H, Yang J, Xiao Q. Global Prevalence of COPD-OSA Overlap Syndrome: A Systematic Review and Meta-Analysis. *Sleep Med*. 2025;:106766. doi:10.1016/j.sleep.2025.106766

54.National Lung Screening Trial Research Team, Aberle D, Adams A. Reduced Lung-Cancer Mortality With Low-Dose Computed Tomographic Screening. *N Engl J Med*. 2011;365(5):395-409. doi:10.1056/NEJMoa1102873

55.US Preventive Services Task Force, Krist A, Davidson K. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2021;325(10):962-970. doi:10.1001/jama.2021.1117

56.Wolf A, Oeffinger K, Shih T. Screening for Lung Cancer: 2023 Guideline Update From the American Cancer Society. *CA Cancer J Clin*. 2024;74(1):. doi:10.3322/caac.21811

57.Broers C, Tack J, Pauwels A. Review Article: Gastro-Oesophageal Reflux Disease in Asthma and Chronic Obstructive Pulmonary Disease. *Aliment Pharmacol Ther*. 2018;47(2):. doi:10.1111/apt.14416

58.Lee A, Goldstein R. Gastroesophageal Reflux Disease in COPD: Links and Risks. *Int J Chron Obstruct Pulmon Dis*. 2015;:1935-1949. doi:10.2147/COPD.S77562

59.Nowalk N, Davis A, Wolfe K. Inhaled Pharmacotherapy for Stable COPD. *JAMA*. Published online June 23, 2025. doi:10.1001/jama.2025.7651

60.Koarai A, Sugiura H, Yamada M. Treatment With LABA Versus LAMA for Stable COPD: A Systematic Review and Meta-Analysis. *BMC Pulm Med*. 2020;20(1):. doi:10.1186/s12890-020-1152-8

61.Maddocks M, Brighton L, Alison J. Rehabilitation for People With Respiratory Disease and Frailty: An Official American Thoracic Society Workshop Report. *Ann Am Thorac Soc*. 2023;20(6):767-780. doi: 10.1513/AnnalsATS.202302-129ST

62.Osadnik C, Brighton L, Burtin C. European Respiratory Society Statement on Frailty in Adults With Chronic Lung Disease. *Eur Respir J*. 2023;62(2):2300442. doi:10.1183/13993003.00442-2023

63.Lindenauer P, Stefan M, Pekow P. Association Between Initiation of Pulmonary Rehabilitation After Hospitalization for COPD and 1-Year Survival Among Medicare Beneficiaries. *JAMA*. 2020;323(18): 1813-1823. doi:10.1001/jama.2020.4437

64.Rabe K, Martinez F, Ferguson G. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. *N Engl J Med*. 2020;383(1):. doi:10.1056/NEJMoa1916046

65.van Geffen W, Tan D, Walters J, Walters E. Inhaled Corticosteroids With Combination Inhaled Long-Acting Beta2-Agonists and Long-Acting Muscarinic Antagonists for Chronic Obstructive Pulmonary Disease. *Cochrane Database Syst Rev*. 2023;:CD011600. doi:10.1002/14651858.CD011600.pub

66.Melén E, Faner R, Allinson J, et al. Lung-Function Trajectories: Relevance and Implementation in Clinical Practice. *Lancet*. 2024;403(10435):1494-1503. doi:10.1016/S0140-6736(24)00016-3

67.GlaxoSmithKline. Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) prescribing information. 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5a81d5a-4648-4c7a-951d-33c014a63c7e

68.Nici L, Mammen M, Charbek E, et al. Pharmacologic Management of Chronic Obstructive Pulmonary Disease: An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2020;201(9):e56-e. doi:10.1164/rccm.202003-0625ST

69.Christenson S, Smith B, Bafadhel M, Putcha N. Chronic Obstructive Pulmonary Disease. *Lancet*. 2022;399(10342):2227-2242. doi:10.1016/S0140-6736(22)00470-6

70.Bhatt S, Rabe K, Hanania N. Dupilumab for COPD With Blood Eosinophil Evidence of Type 2 Inflammation. *N Engl J Med*. 2024;390(24):2274-2283. doi:10.1056/NEJMoa2401304

71.Bhatt S, Rabe K, Hanania N. Dupilumab for COPD With Type 2 Inflammation Indicated by Eosinophil Counts. *N Engl J Med*. 2023;389(3):205-214. doi:10.1056/NEJMoa2303951

72.Jacobs S, Krishnan J, Lederer D. Home Oxygen Therapy for Adults With Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2020;202(10):e121-e. doi:10.1164/rccm.202009-3608ST

73.AstraZeneca. Breztri Aerosphere (budesonide, glycopyrrolate, and formoterol fumarate) prescribing information. 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c

74.Takeda. Glassia (alpha-1-proteinase inhibitor human) prescribing information. 2010. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83473cbb-48e4-42a2-81b6-4c851423da7b

75.Chapman K, Burdon J, Piitulainen E. Intravenous Augmentation Treatment and Lung Density in Severe Alpha-1 Antitrypsin Deficiency (RAPID): A Randomised, Double-Blind, Placebo-Controlled Trial. *Lancet*. 2015;386(9991):360-368. doi:10.1016/S0140-6736(15)60860-1

76.Fraughen D, Ghosh A, Hobbs B. Augmentation Therapy for Severe Alpha-1 Antitrypsin Deficiency Improves Survival and Is Decoupled From Spirometric Decline: A Multinational Registry Analysis. *Am J Respir Crit Care Med*. 2023;208(9):964-974. doi:10.1164/rccm.202305-0863OC

77.Department of Veterans Affairs, Department of Defense. *Management of Chronic Obstructive Pulmonary Disease (COPD)*. Department of Veterans Affairs; 2021. https://www.healthquality.va.gov/guidelines/CD/copd/VADODCOPDCPGFinal508.pdf

78.Rochester C, Alison J, Carlin B. Pulmonary Rehabilitation for Adults With Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2023;208(4):e7-e. doi:10.1164/rccm.202306-1066ST

79.Black C, Kriss J, Razzaghi H. Influenza, Updated COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults - United States, Fall 2023. *MMWR Morb Mortal Wkly Rep*. 2023;72(51):1377-1382. doi:10.15585/mmwr.mm7251a

80.Howcroft M, Walters E, Wood-Baker R, Walters J. Action Plans With Brief Patient Education for Exacerbations in Chronic Obstructive Pulmonary Disease. *Cochrane Database Syst Rev*. 2016;(12):CD005074. doi:10.1002/14651858.CD005074.pub

81.Tran M, Xiang P, Rascati K. Predictors of Appropriate Pharmacotherapy Management of COPD Exacerbations and Impact on 6-Month Readmission. *J Manag Care Spec Pharm*. 2016;22(10):1186-1193. doi:10.18553/jmcp.2016.22.10.1186

82.Celli B, Fabbri L, Yohannes A, et al. A Person-Centred Clinical Approach to the Multimorbid Patient With COPD. *Eur J Intern Med*. Published online August 12, 2025. doi:10.1016/j.ejim.2025.07.020

83.Finks S, Rumbak M, Self T. Treating Hypertension in Chronic Obstructive Pulmonary Disease. *N Engl J Med*. 2020;382(4):353-363. doi:10.1056/NEJMra1805377

84.Yang Y, Xiang Z, Yang J, Wang W, Xu Y, Huang C. Association of Beta-Blocker Use With Survival and Pulmonary Function in Patients With Chronic Obstructive Pulmonary and Cardiovascular Disease: A Systematic Review and Meta-Analysis. *Eur Heart J*. 2020;41(46):4415-4422. doi:10.1093/eurheartj/ehaa793

85.Golubic R, Mumbole H, Ismail M. Glucocorticoid Treatment and New-Onset Hyperglycaemia and Diabetes in People Living With Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. *Diabet Med*. 2025;42(3):e15475. doi:10.1111/dme.15475

86.Baillargeon J, Singh G, Kuo Y, Raji M, Westra J, Sharma G. Association of Opioid and Benzodiazepine Use With Adverse Respiratory Events in Older Adults With Chronic Obstructive Pulmonary Disease. *Ann Am Thorac Soc*. 2019;16(10):1245-1251. doi:10.1513/AnnalsATS.201901-024OC

87.Yohannes A, Jin J, Kunik M. Benefit-Risk Assessment of Psychotropic Drugs in Older Patients With Chronic Obstructive Pulmonary Disease. *Drugs Aging*. 2022;39(5):323-332. doi:10.1007/s40266-022-00935-0

88.Yang I, Ferry O, Clarke M, Sim E, Fong K. Inhaled Corticosteroids Versus Placebo for Stable Chronic Obstructive Pulmonary Disease. *Cochrane Database Syst Rev*. 2023;(3):CD002991. doi:10.1002/14651858.CD002991.pub

89.Huang C, Liu Y, Shi G. A Systematic Review With Meta-Analysis of Gastroesophageal Reflux Disease and Exacerbations of Chronic Obstructive Pulmonary Disease. *BMC Pulm Med*. 2020;20(1):. doi:10.1186/s12890-019-1027-z

90.Kikuchi S, Imai H, Tani Y, Tajiri T, Watanabe N. Proton Pump Inhibitors for Chronic Obstructive Pulmonary Disease. *Cochrane Database Syst Rev*. 2020;(8):CD013113. doi:10.1002/14651858.CD013113.pub

91.GoodRx. Trelegy Ellipta Prices, Coupons & Savings Tips. 2026. https://www.goodrx.com/trelegy-ellipta

92. GoodRx. Breztri Aerosphere Prices, Coupons & Savings Tips. 2026. https://www.goodrx.com/breztri-aerosphere

MEDICAL DISCLAIMER

The information provided by the American Academy of Value-Based Care (AAVBC) in this document, including but not limited to coding guidance, and related content, is intended for educational and informational purposes only. This content is designed to assist healthcare providers, organizations, and professionals in understanding and applying Value-Based Care principles, practices, and regulatory compliance standards.

AAVBC does not provide legal, clinical, or medical advice. The content presented should not be interpreted or relied upon as specific legal, medical, clinical, or professional guidance. While efforts are made to ensure the accuracy and currency of the information provided, AAVBC does not guarantee that the materials presented are complete, comprehensive, or without error.

Providers and healthcare professionals must independently evaluate all content and guidance presented herein in the context of applicable laws, regulations, clinical guidelines, payer policies, patient-specific conditions, and contraindications. Any treatments, procedures, diagnostic approaches, medications, or strategies discussed are illustrative and should not be directly applied without a thorough and independent review of current, evidence-based clinical resources, and regulatory requirements.

For coding, documentation, utilization management, quality measures (including STAR ratings), and compliance matters, users are responsible for consulting official guidance issued by regulatory bodies, including but not limited to the Centers for Medicare & Medicaid Services (CMS), the American Medical Association (AMA), relevant state agencies, and other authoritative entities.

AAVBC expressly disclaims liability for any loss, claim, or damage arising directly or indirectly from the use of or reliance on information provided in this document. Users should consult their organization's legal counsel, compliance officer, or qualified professional advisor for advice specific to their situation.

By accessing and using this document, you agree to AAVBC's terms and acknowledge that the use of the content is at your own risk and discretion.